[go: up one dir, main page]

WO2002011510A1 - Nouveau polypeptide, proteine orf2 humaine 21 a element de type l1, et polynucleotide codant ce polypeptide - Google Patents

Nouveau polypeptide, proteine orf2 humaine 21 a element de type l1, et polynucleotide codant ce polypeptide Download PDF

Info

Publication number
WO2002011510A1
WO2002011510A1 PCT/CN2001/001002 CN0101002W WO0211510A1 WO 2002011510 A1 WO2002011510 A1 WO 2002011510A1 CN 0101002 W CN0101002 W CN 0101002W WO 0211510 A1 WO0211510 A1 WO 0211510A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
human
protein
polynucleotide
element class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2001/001002
Other languages
English (en)
French (fr)
Inventor
Yumin Mao
Yi Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Biowindow Gene Development Inc
Original Assignee
Shanghai Biowindow Gene Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc
Priority to AU93633/01A priority Critical patent/AU9363301A/en
Publication of WO2002011510A1 publication Critical patent/WO2002011510A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention belongs to the field of biotechnology. Specifically, the present invention describes a novel polypeptide, a human L1 element class, the ORF2 protein 21, and a polynucleotide sequence encoding the polypeptide. The invention also relates to a preparation method and application of the polynucleotide and the polypeptide. Background technique
  • the main human genome is made up of several unique DM sequences, which are interspersed with many different families containing repeats. These interspersed repeating elements can be classified according to their genome length. Members of a family that scatter repeats of short sequences, such as Alu repeats, are called SINEs, and members of a family that scatter repeats of long sequences are called LINEs. Human long interspersed repeats LINE-1 (L1) constitute a highly repetitive DNA family that lacks long terminal repeats. Some L1 elements are capable of retrotransposition in the mammalian genome. The L1 sequence is characterized by an A-rich fragment at the 3 'end, a truncated 5, end, and a significant extension of the long open reading frames (ORFs).
  • ORFs long open reading frames
  • the consensus sequence in the complete L1 element is 6.5 kb in length and contains two open reading frames (0RF1 and 0RF2).
  • ORF1 encodes a 40-kDa protein
  • ORF2 has a region that is identical in sequence to reverse transcriptase.
  • the nucleotide sequences of the two open reading frame regions and the polypeptide chains of the two open reading frames are homologous in all mammalian cells. It has L1 transcriptional activity in many solid tumors and tumor cells. Studies have shown that there is an internal cis element that is important for human L1 transcription and a nuclear factor that binds to this element, which indicates that some members of the L1 family are functional genes encoding one or several conserved polypeptides.
  • L1 transcription is relatively human specific, and its transcriptional function in cells is critical for proliferation (Dombroski, BA, Scot t, AF, and Kazazian, HH, Jr. (1993) Proc Nat l Acad. Sci USA 90, 6513-6517).
  • L1 element class ORF2 protein The expression of the L1 transcription factor is relatively human-specific and is very important for cell proliferation.
  • the main nucleotide sequence of the L1 element class ORF2 protein is related to that of human retinoblastoma (Rb), IL-2, and factor VI II genes. The sequences are highly homologous.
  • the Rb and Factor VI II genes have high frequency of chromosome deletions in different cancers, so long integration of long homologous L1 elements in genes and chromosomes will cause abnormal DNA arrangements (Kou- Wha Kuo, Harara- Ming Sheu , Yu-Sheng Huang, Biochemica l and Biophys i cal Research Communicat ions 253, 566-570 (1998)).
  • the novel human L1 element class 0RF2 protein of the present invention has 64% identity and 81% similarity at the protein level with human L 1 element class 0RF2 protein, and also contains those shared by other members of the L1 element class 0RF2 protein family.
  • the various characteristic sequence fragments, both of which are members of the L1 element class 0RF2 protein family, and have similar biological functions, are named human L1 element class 0RF2 protein 21.
  • This protein is very important for cell proliferation, and its abnormal expression will usually lead to abnormal DM arrangement and cause various cancers, such as retinoblastoma b), small cell lung cancer and other diseases.
  • the human L1 element-like 0RF2 protein 21 protein plays an important role in regulating important functions of the body such as cell division and embryonic development, and it is believed that a large number of proteins are involved in these regulatory processes, so it has been necessary to identify more involved in these Process the human L1 element class ORF2 protein 21 protein, especially the amino acid sequence of this protein is identified.
  • the isolation of the newcomer L1 element class 0RF2 protein 21 protein encoding gene also provides a basis for research to determine the role of this protein in health and disease states. This protein may form the basis for the development of diagnostic and / or therapeutic drugs for the disease, so isolation of its coding DNA is very important. Disclosure of invention
  • Another object of the invention is to provide a polynucleotide encoding the polypeptide.
  • Another object of the present invention is to provide a recombinant vector containing a polynucleotide encoding a human L1 element class ORF2 protein 21.
  • Another object of the present invention is to provide a genetically engineered host cell comprising a polynucleotide encoding a human L 1 element class ORF2 protein 21.
  • Another object of the present invention is to provide a method for producing the human L1 element class ORF2 protein 21.
  • Another object of the present invention is to provide an antibody against the polypeptide of the present invention-human L 1 element type ORF2 protein 2 1.
  • Another object of the present invention is to provide mimic compounds, antagonists, agonists, and inhibitors directed to the polypeptide of the present invention-human L1 element class ORF2 protein 21.
  • Another object of the present invention is to provide a method for diagnosing and treating diseases associated with abnormalities in the human L1 element class ORF2 protein 21.
  • the present invention relates to an isolated polypeptide, which is of human origin and comprises: a polypeptide having the amino acid sequence of SEQ ID No. 2, or a conservative variant, biologically active fragment or derivative thereof.
  • the multiple The peptide is a polypeptide having the amino acid sequence of SEQ ID NO: 2.
  • the invention also relates to an isolated polynucleotide comprising a nucleotide sequence or a variant thereof selected from the group consisting of:
  • sequence of the polynucleotide is one selected from the group consisting of: (a) a sequence having positions 860-1426 in SEQ ID NO: 1; and (b) a sequence having 1-1467 in SEQ ID NO: 1 Sequence of bits.
  • the invention further relates to a vector, in particular an expression vector, incorporating the polynucleotide of the invention; a host cell genetically engineered with the vector, including a transformed, transduced or transfected host cell; The method for preparing a polypeptide of the present invention by describing a host cell and recovering an expressed product is described.
  • the invention also relates to an antibody capable of specifically binding to a polypeptide of the invention.
  • the invention also relates to a method for screening compounds that mimic, activate, antagonize or inhibit human L1 element class RFF2 protein 21 protein activity, which comprises utilizing the polypeptide of the invention.
  • the invention also relates to compounds obtained by this method.
  • the invention also relates to a method for in vitro detection of a disease or disease susceptibility associated with abnormal expression of the human L1 element class 0RF2 protein 21 protein, which comprises detecting a mutation in the polypeptide or a polynucleotide sequence encoding the same in a biological sample, or detecting The amount or biological activity of a polypeptide of the invention in a biological sample.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a polypeptide of the invention or a mimetic thereof, an activator, an antagonist or an inhibitor, and a pharmaceutically acceptable carrier.
  • the present invention also relates to the use of the polypeptide and / or polynucleotide of the present invention in the preparation of a medicament for the treatment of cancer, developmental disease or immune disease or other diseases caused by abnormal expression of human L1 element class 0RF2 protein 21.
  • Nucleic acid sequence refers to an oligonucleotide, a nucleotide or a polynucleotide and a fragment or part thereof, and may also refer to a genomic or synthetic DM or RM, they can be single-stranded or double-stranded, representing the sense or antisense strand.
  • amino acid sequence refers to an oligopeptide, peptide, polypeptide or protein sequence and fragments or portions thereof.
  • amino acid sequence in the present invention relates to the amino acid sequence of a naturally occurring protein molecule
  • polypeptide or “protein” does not mean to limit the amino acid sequence to a complete natural amino acid related to the protein molecule .
  • a protein or polynucleotide “variant” refers to an amino acid sequence having one or more amino acids or nucleotide changes, or a polynucleotide sequence encoding it. The changes may include deletions, insertions or substitutions of amino acids or nucleotides in the amino acid sequence or nucleotide sequence.
  • Variants may have "conservative" changes in which the substituted amino acid has a structural or chemical property similar to the original amino acid, such as replacing isoleucine with leucine. Variants can also have non-conservative changes, such as replacing glycine with tryptophan.
  • “Deletion” refers to the deletion of one or more amino acids or nucleotides in an amino acid sequence or nucleotide sequence.
  • Insertion refers to an alteration in the amino acid sequence or nucleotide sequence that results in an increase in one or more amino acids or nucleotides compared to a naturally occurring molecule.
  • Replacement refers to the replacement of one or more amino acids or nucleotides with different amino acids or nucleotides.
  • Bioactivity refers to a protein that has the structure, regulation, or biochemical function of a natural molecule.
  • immunologically active refers to the ability of natural, recombinant or synthetic proteins and fragments thereof to induce a specific immune response in appropriate animals or cells and to bind to specific antibodies.
  • An "agonist” refers to a molecule that, when combined with the human L1 element class 0RF2 protein 21, causes a change in the protein to regulate the activity of the protein.
  • An agonist may include a protein, a nucleic acid, a carbohydrate, or any other molecule that can bind to the human L1 element class ORF2 protein 21.
  • Antagonist refers to a molecule that can block or regulate the biological or immunological activity of the human L1 element class 0RF2 protein 21 when combined with the human L1 element class 0RF2 protein 21.
  • Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecule that can bind to the human L1 element class ORF2 protein 21.
  • “Regulation” refers to a change in the function of human L1 element class 0RF2 protein 21, including an increase or decrease in protein activity, a change in binding characteristics, and any other biological, functional, or immune properties of human L1 element class 0RF2 protein 21. change.
  • “Substantially pure '” means essentially free of other proteins, lipids, carbohydrates or other substances with which it is naturally associated.
  • Those skilled in the art can purify human L1 element class RFF2 protein 21 using standard protein purification techniques.
  • Basic The pure human L1 element class 0RF2 protein 21 can generate a single main band on a non-reducing polyacrylamide gel.
  • the purity of the human L1 element class 0RF2 protein 21 polypeptide can be analyzed by amino acid sequence.
  • Complementary refers to the natural binding of polynucleotides by base-pairing under conditions of acceptable salt concentration and temperature.
  • sequence C-T-G-A
  • complementary sequence G-A-C-T.
  • the complementarity between two single-stranded molecules may be partial or complete.
  • the degree of complementarity between nucleic acid strands has a significant effect on the efficiency and strength of hybridization between nucleic acid strands.
  • “Homology” refers to the degree of complementarity and can be partially homologous or completely homologous.
  • Partial homology A partially complementary sequence that at least partially inhibits the hybridization of a fully complementary sequence to a target nucleic acid. The inhibition of such hybridization can be detected by performing hybridization (Southern blotting or Nor thern blotting, etc.) under conditions of reduced stringency. Substantially homologous sequences or hybridization probes can compete and inhibit the binding of completely homologous sequences to the target sequence under conditions of reduced stringency. This does not mean that the conditions of reduced stringency allow non-specific binding, because the conditions of reduced stringency require that the two sequences bind to each other as a specific or selective interaction.
  • Percent identity refers to the percentage of sequences that are the same or similar in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, such as through the MEGALIGN program
  • the MEGALIGN program can compare two or more sequences according to different methods such as the Clus ter method (Hi gg ins, D. G, and PM Sharp (1988) Gene 73: 237-244). 0 The Clus ter method checks all pairs The distances of each group are arranged into clusters. The clusters are then assigned in pairs or groups.
  • the percent identity between two amino acid sequences such as sequence A and sequence B is calculated by the following formula: The number of matching residues between sequence A and sequence X 100 The number of residues in sequence A-the number of spacer residues in sequence A The number of spacer residues in a sequence B can also be determined by Clus ter method or using methods known in the art such as Jotun Hein.
  • the percent identity between nucleic acid sequences (Hein J., (1990) Methods in emzumology 183: 625-645) 0 "Similarity" refers to the degree of identical or conservative substitutions of amino acid residues at corresponding positions in the alignment of amino acid sequences.
  • Amino acids used for conservative substitutions may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; having an uncharged head group is Similar hydrophilic amino acids may include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.
  • Antisense refers to a nucleotide sequence that is complementary to a particular DNA or RNA sequence.
  • Antisense strand refers to a nucleic acid strand that is complementary to a “sense strand.”
  • Derivative refers to a chemical modification of HFP or a nucleic acid encoding it. This chemical modification may be a substitution of a hydrogen atom with a fluorenyl, acyl or amino group. Nucleic acid derivatives can encode polypeptides that retain the main biological properties of natural molecules.
  • Antibody refers to a complete antibody molecule and its fragments, such as Fa,? (& 1) ') 2 and? , It can specifically bind to the epitope of human L1 element class 0RF2 protein 21.
  • a “humanized antibody” refers to an antibody in which the amino acid sequence of a non-antigen binding region is replaced to become more similar to a human antibody, but still retains the original binding activity.
  • isolated refers to the removal of a substance from its original environment (for example, its natural environment if it is naturally occurring).
  • a naturally-occurring polynucleotide or polypeptide is not isolated when it is present in a living thing, but the same polynucleotide or polypeptide is separated from some or all of the substances that coexist with it in the natural system.
  • Such a polynucleotide may be part of a certain vector, or such a polynucleotide or polypeptide may be part of a certain composition. Since the carrier or composition is not part of its natural environment, they are still isolated.
  • isolated refers to the separation of a substance from its original environment (if it is a natural substance, the original environment is the natural environment).
  • polynucleotides and polypeptides in a natural state in a living cell are not isolated and purified, but the same polynucleotides or polypeptides are separated and purified if they are separated from other substances in the natural state .
  • isolated human L1 element class 0RF2 protein 21 refers to human L1 element class 0RF2 protein 21 which is substantially free of other proteins, lipids, carbohydrates or other substances naturally associated with it.
  • Those skilled in the art can purify the human L1 element class ORF2 protein 21 using standard protein purification techniques. Substantially pure peptides can produce a single main band on a non-reducing polyacrylamide gel. The purity of human L1 element class 0RF2 protein 21 peptide can be analyzed by amino acid sequence.
  • the present invention provides a novel polypeptide-human L1 element class RFF2 protein 21, which is basically composed of the amino acid sequence shown in SEQ ID NO: 2.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide, and preferably a recombinant polypeptide.
  • the polypeptides of the invention can be naturally purified products, or chemically synthesized products, or produced using recombinant techniques from prokaryotic or eukaryotic hosts (e.g., bacteria, yeast, higher plants, insects, and mammalian cells). Depending on the host used in the recombinant production protocol, the polypeptide of the invention may be glycosylated, or it may be non-glycosylated. Polypeptides of the invention may also include or exclude starting methionine residues.
  • the invention also includes fragments, derivatives, and analogs of the human L1 element class ORF2 protein 21.
  • fragment refers to a polypeptide that substantially maintains the same biological function or activity of the human L1 element class ORF2 protein 21 of the present invention.
  • a fragment, derivative or analog of the polypeptide of the present invention may be: U) a type in which one or more amino acid residues are substituted with conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the substituted An amino acid may or may not be encoded by a genetic code; or ( ⁇ ) such a type in which a group on one or more amino acid residues is substituted by another group to include a substituent; or (III) such a Species, wherein the mature polypeptide is fused to another compound (such as a compound that prolongs the polypeptide's half-life, such as polyethylene glycol); or (IV) such that the additional amino acid sequence is fused to the mature polypeptide
  • the resulting polypeptide sequence (such as a leader sequence or a secreted sequence or a sequence used to purify the polypeptide or a protein sequence).
  • such fragments, derivatives, and analogs are considered to be within the scope of those skilled in the art.
  • the present invention provides an isolated nucleic acid (polynucleotide), which basically consists of a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2.
  • the polynucleotide sequence of the present invention includes the nucleotide sequence of SBQ ID NO: 1.
  • the polynucleotide of the present invention is found from a cDNA library of human fetal brain tissue. It contains a polynucleotide sequence of 1467 bases in length and its open reading frame of 860-1426 encodes 188 amino acids.
  • this polypeptide has 64% homology with the human L1 element class 0RF2 protein, and it can be deduced that the human L1 element class 0RF2 protein 21 has a similar structure and function as the human L1 element class 0RF2 protein.
  • the polynucleotide of the present invention may be in the form of DNA or MA.
  • DNA forms include cDNA, genomic DNA, or synthetic DNA.
  • DNA can be single-stranded or double-stranded.
  • DNA can be coding or non-coding.
  • the coding region sequence encoding a mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant.
  • a "degenerate variant" refers to a nucleic acid sequence encoding a protein or polypeptide having SEQ ID NO: 2 in the present invention, but which differs from the coding region sequence shown in SEQ ID NO: 1.
  • the polynucleotide encoding the mature polypeptide of SEQ ID NO: 2 includes: only the coding sequence of the mature polypeptide; the coding sequence of the mature polypeptide and various additional coding sequences; the coding sequence of the mature polypeptide (and optional additional coding sequences); Coding sequence.
  • polynucleotide encoding a polypeptide refers to a polynucleotide comprising the polypeptide and a polynucleotide comprising additional coding and / or non-coding sequences.
  • the invention also relates to variants of the polynucleotides described above, which encode polypeptides or fragments, analogs and derivatives of polypeptides having the same amino acid sequence as the invention.
  • Variants of this polynucleotide can be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
  • an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .
  • the invention also relates to a polynucleotide that hybridizes to the sequence described above (having at least 50%, preferably 70% identity between the two sequences).
  • the invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the invention under stringent conditions.
  • "strict conditions” means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1 /.
  • hybridizable polynucleotide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO: 2.
  • nucleic acid fragments that hybridize to the sequences described above.
  • a "nucleic acid fragment” contains at least 10 nucleotides in length, preferably at least 20-30 nucleotides, more preferably at least 50-60 nucleotides, and most preferably at least 100 nuclei. Glycylic acid or more. Nucleic acid fragments can also be used in nucleic acid amplification techniques (such as PCR) to identify and / or isolate polynucleotides encoding human L1 element class 0RF2 protein 21.
  • polypeptides and polynucleotides in the present invention are preferably provided in an isolated form and are more preferably purified to homogeneity.
  • the specific polynucleotide sequence encoding the human L1 element class ORF2 protein 21 of the present invention can be obtained by various methods.
  • polynucleotides are isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect homologous polynucleotide sequences, and 2) antibody screening of expression libraries to detect cloned polynucleosides with common structural characteristics Acid fragments.
  • the DM fragment sequence of the present invention can also be obtained by the following methods: 1) isolating the double-stranded DNA sequence from the genomic DNA; 2) chemically synthesizing the DNA sequence to obtain the double-stranded DNA of the polypeptide.
  • genomic DNA isolation is the least commonly used. Direct chemical synthesis of DNA sequences is often the method of choice. The more commonly used method is the isolation of cDNA sequences.
  • the standard method for isolating cDNA of interest is to isolate mRNA from donor cells that overexpress the gene and perform reverse transcription to form a plasmid or phage cDNA library. There are many mature techniques for mRNA extraction, and kits are also commercially available (Q i agene).
  • the construction of cDNA libraries is also a common method (Sambrook, eta l., Mol ecu l ar Cl oning, A Labora tory Manua l, Cold Spr ing Harbor Labora tory. New York, 1989).
  • CDNA libraries are also commercially available For example, different cDNA libraries from Clontech. When polymerase reaction technology is used in combination, even very few expression products can be cloned.
  • genes of the present invention can be screened from these cDM libraries by conventional methods. These methods include (but are not limited to): (l) DNA-DNA or DM-RM hybridization; (2) the presence or absence of marker gene function; (3) determination of the level of the transcript of the human L1 element class ORF2 protein 21; ( 4) Detecting gene-expressed protein products by immunological techniques or by measuring biological activity. The above methods can be used singly or in combination.
  • the probe used for hybridization is homologous to any part of the polynucleotide of the present invention, and its length is at least 10 nucleotides, preferably at least 30 nucleotides, more preferably Is at least 50 nucleotides, preferably at least 100 nucleotides. In addition, the length of the probe is usually within 2000 nucleotides, preferably within 1000 nucleotides.
  • the probe used herein is generally a DNA sequence chemically synthesized based on the gene sequence information of the present invention. The genes or fragments of the present invention can of course be used as probes. DNA probes can be labeled with radioisotopes, luciferin, or enzymes (such as alkaline phosphatase).
  • immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA) can be used to detect the protein product of the human L1 element class 0RF2 protein 21 gene expression.
  • the RACE method RACE-cDM terminal rapid amplification method
  • the primers used for PCR may be appropriately based on the polynucleotide sequence information of the present invention disclosed herein.
  • the amplified DM / RNA fragment can be isolated and purified by conventional methods such as by gel electrophoresis.
  • polynucleotide sequence of the gene of the present invention or various DNA fragments and the like obtained as described above can be determined by a conventional method such as dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such polynucleotide sequences can also be determined using commercial sequencing kits and the like. In order to obtain the full-length cDNA sequence, the sequencing must be repeated. Sometimes it is necessary to determine the cMA sequence of multiple clones in order to splice into a full-length cDNA sequence.
  • the present invention also relates to a vector comprising the polynucleotide of the present invention, and a host cell produced by genetic engineering using the vector of the present invention or directly using the human L1 element class 0RF2 protein 21 coding sequence, and a recombinant technology for producing the polypeptide of the present invention. method.
  • a polynucleotide sequence encoding the human L1 element class ORF2 protein 21 can be inserted into a vector to constitute a recombinant vector containing the polynucleotide of the present invention.
  • vector refers to bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors well known in the art.
  • Vectors suitable for use in the present invention include, but are not limited to: T7 promoter-based expression vectors (Rosenberg, et al. Gene, 1987, 56: 125) expressed in bacteria; pMSXND expression vectors expressed in mammalian cells ( Lee and Nathans, J Bio Chem.
  • any plasmid and vector can be used to construct a recombinant expression vector.
  • An important feature of expression vectors is that they usually contain an origin of replication, a promoter, a marker gene, and translational regulatory elements.
  • the DNA sequence can be operably linked to an appropriate promoter in an expression vector to guide mRNA synthesis.
  • promoters are: the lac or trp promoter of E. coli; the PL promoter of lambda phage; eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, early and late SV40 promoter, retroviral LTRs and other known promoters that can control the expression of genes in prokaryotic or eukaryotic cells or their viruses.
  • the expression vector also includes a ribosome binding site and a transcription terminator for translation initiation. Insertion of enhancer sequences into the vector will enhance its transcription in higher eukaryotic cells.
  • Enhancers are cis-acting factors for DNA expression, usually about 10 to 300 base pairs, which act on promoters to enhance gene transcription.
  • Illustrative examples include SV40 enhancers of 100 to 270 base pairs on the late side of the origin of replication, polyoma enhancers on the late side of the origin of replication, and adenoviral enhancers.
  • the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
  • selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
  • GFP fluorescent protein
  • tetracycline or ampicillin resistance for E. coli.
  • a polynucleotide encoding the human L1 element class ORF2 protein 21 or a recombinant vector containing the polynucleotide can be transformed or transduced into a host cell to constitute a genetically engineered host cell containing the polynucleotide or the recombinant vector.
  • the term "host cell” refers to a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples are: E.
  • coli Streptomyces
  • bacterial cells such as Salmonella typhimurium
  • fungal cells such as yeast
  • plant cells insect cells
  • fly S2 or Sf 9 animal cells
  • animal cells such as CH0, COS or Bowes s melanoma cells, etc. .
  • Transformation of a host cell with a DNA sequence described in the present invention or a recombinant vector containing the DNA sequence can be performed using conventional techniques well known to those skilled in the art.
  • the host is a prokaryote such as E. coli
  • competent cells capable of DNA uptake can be in the exponential growth phase were harvested, treated with (Method 12, using the procedure well known in the art.
  • Alternative is MgC l 2.
  • transformation can also be performed by electroporation.
  • the following DNA transfection methods can be used: calcium phosphate co-precipitation method, or conventional mechanical methods such as microinjection, electroporation, and liposomes Packaging, etc.
  • polynucleotide sequence of the present invention can be used to express or produce recombinant human L1 element class RFF2 protein 21 (Scence, 1984; 224: 1431). Generally there are the following steps:
  • the medium used in the culture may be selected from various Conventional medium. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
  • a suitable method such as temperature conversion or chemical induction
  • the recombinant polypeptide may be coated in a cell, expressed on a cell membrane, or secreted outside the cell.
  • recombinant proteins can be separated and purified by various separation methods using their physical, chemical and other properties. These methods are well known to those skilled in the art. These methods include, but are not limited to: conventional renaturation treatment, protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
  • conventional renaturation treatment protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid chromatography
  • Fig. 1 is a comparison diagram of the amino acid sequence homology between the LRF element class 0RF2 protein 21 and the human L1 element class 0RF2 protein.
  • the upper sequence is the human L1 element class 0RF2 protein 21 and the lower sequence is the human L1 element class 0RF2 protein.
  • Identical amino acids are represented by single-character amino acids between the two sequences, and similar amino acids are represented by "+”.
  • Figure 2 shows the polyacrylamide gel electrophoresis (SDS-PAGE) of the isolated human L1 element class 0RF2 protein 21.
  • 21 kDa is the molecular weight of the protein.
  • the arrow indicates the isolated protein band.
  • Total human fetal brain RNA was extracted by one-step method with guanidine isothiocyanate / phenol / chloroform.
  • Poly (A) raRNA was isolated from total RNA using Quik mRNA Isolat ion Kit (product of Qiegene). 2ug poly (A) mRNA is reverse transcribed to form cDNA.
  • the Smart cDNA cloning kit purchased from Clontech) was used to insert the cDNA fragments into the multiple cloning site of pBSK (+) vector (Clontech) to transform DH5c.
  • the bacteria formed a CDM library.
  • Dye terminate cycle react ion sequencing kit Perkin-Elmer
  • ABI 377 An automatic sequencer (Perkin-Elmer) determined the sequences at the 5 'and 3' ends of all clones. The determined cDNA sequence was compared with the existing public DNA sequence database (Genebank), and it was found that the cDNA sequence of one of the clones 2448e04 was new DNA. A series of primers were synthesized to determine the inserted cDNA fragments of the clone in both directions.
  • the 2448e04 clone contained a full-length cDNA of 1467bp (as shown in Seq ID NO: 1), and a 567bp open reading frame (0RF) from 860bp to 1426bp, encoding a new protein (such as Seq ID NO : Shown in 2).
  • This clone pBS-2448e04 and the encoded protein was named human L1 element class 0RF2 protein 21.
  • the sequence of the human L1 element class ORF2 protein 21 of the present invention and its encoded protein sequence were analyzed using the Blas t program (Basicloca l Al ignment search tool) [Al schul, SF et al.
  • the gene with the highest homology to the human L1 element class 0RF2 protein 21 of the present invention is a known human L1 element class 0RF2 protein, and the accession number of the encoded protein in Genbank is AF003535.
  • the protein homology results are shown in Figure 1. The two are highly homologous, with an identity of 64% and a similarity of 81%.
  • Example 3 Cloning of a gene encoding human L1 element class 0RF2 protein 21 by RT-PCR
  • CDNA was synthesized using fetal brain total RNA as a template and ol igo-dT as a primer for reverse transcription reaction. After purification with Qiagene's kit, the following primers were used for PCR amplification:
  • Primer2 5,-CATAGGCCGAGGCGGCCGACATGT -3, (SEQ ID NO: 4)
  • Pr imerl is a forward sequence located at the 5th end of SEQ ID NO: 1, starting at lbp;
  • Pr imer2 is the 3'-end reverse sequence in SEQ ID NO: 1.
  • Amplification conditions 50 mmol / L KC1, 10 mmol / L Tr is-Cl, (pH 8. 5), 1.5 ol / L MgCl 2 , 200 ⁇ mol / L dNTP in a reaction volume of 50 ⁇ 1 , l Opmol primer, 1U Taq DM polymerase (Clontech).
  • the reaction was performed on a PE9600 DNA thermal cycler (Perkin-Elmer) for 25 cycles under the following conditions: 94 ° C 30sec; 55. C 30sec; 72 ° C 2min.
  • RT-PCR set ⁇ -act in as a positive control and template blank as a negative control.
  • the amplified product was purified using a QIAGEN kit and ligated to a pCR vector (Invitrogen) using a TA cloning kit.
  • the DNA sequence analysis results showed that the DNA sequence of the PCR product was exactly the same as l-1467bp shown in SEQ ID NO: 1.
  • Example 4 Northern blot analysis of human L1 element class 0RF2 protein 21 gene expression:
  • RNA extraction in one step [Anal. Biochera 1987, 162, 156-159].
  • This method involves acid guanidinium thiocyanate phenol-chloroform extraction. That is, the tissue is homogenized with 4M guanidine isothiocyanate-25mM sodium citrate, 0.2M sodium acetate (pH 4.0), and 1 volume of phenol and 1/5 volume of chloroform-isoamyl alcohol (49: 1), leave after mixing Heart. Aspirate the aqueous layer, add isopropanol (0.8 vol) and centrifuge the mixture to obtain RNA precipitate. The resulting RNA pellet was washed with 70% ethanol, dried and dissolved in water.
  • the 32P- labeled probes (about 2 xl 0 6 cpm / ml) and RNA was transferred to a nitrocellulose membrane overnight at 42 ° C in a hybridization solution, the solution comprising 50% formamide -25mM KH 2 P0 4 (pH7. 4) -5 x SSC-5 x Denhardt's solution and 200 yg / ml salmon sperm DNA.
  • the filter was washed in 1 x SSC-0.1% SDS at 55 ° C for 30 min. Then, Phosphor Imager was used for analysis and quantification.
  • Example 5 In vitro expression, isolation and purification of recombinant human L1 element class ORF2 protein 21
  • Pr imer3 5 '-CCCCATATGATGCTCTCTCTCGCCACTTCTATT-3' (Seq ID No: 5)
  • Pr imer4 5,-CATGGATCCCTACATGAATTTAAAACTAGTTTT- 3, (Seq ID No: 6)
  • the 5 'ends of these two primers contain Ndel and BamHI digestion sites, respectively, followed by the coding sequences of the 5' and 3 'ends of the target gene, respectively.
  • the Ndel and BamHI restriction sites correspond to the selective endonuclease sites on the expression vector plasmid pET-28b (+) (Novagen, Cat. No. 69865. 3).
  • the PCR reaction was performed using the pBS-2448e04 plasmid containing the full-length target gene as a template.
  • the PCR reaction conditions were as follows: a total volume of 50 ⁇ 1 containing 10 pg of pBS-2448e04 plasmid, primers Pr iraer-3 and Pr imer-4 were added separately! ] Is 1 Opmol, Advantage polymerase Mix (Clontech) 1 ⁇ 1. Cycle parameters: 94 ° C 20s, 60 ° C 30s, 68. C 2 min, a total of 25 cycles. Ndel and BamHI were used to double-digest the amplified product and plasmid ⁇ 1 "-28 (+), respectively, and large fragments were recovered and ligated with T4 ligase. The ligation products were transformed by the calcium chloride method of coliform bacteria DH5a.
  • the positive clones were screened by colony PCR method and sequenced.
  • the positive clones with the correct sequence were selected with calcium chloride.
  • the recombinant plasmid was transformed into Escherichia coli BL21 (DE3) plySs (product of Novagen).
  • the host strain BL21 (pET-2448e04) Cultivate to logarithmic growth phase, add IPTG to a final concentration of 1mmol / L, and continue the cultivation for 5 hours.
  • a peptide synthesizer (product of PE company) was used to synthesize the following polypeptide specific for the human L1 element type RFF2 protein 21: NH2-Met-Leu-Ser-Leu-Ala-Thr-Ser-I le-Gln-His-Ser- Thr-Gly-Ser-Pro-C00H (SEQ ID Album: 7).
  • the peptide was coupled with hemocyanin and bovine serum albumin to form a complex. For the method, see: Avrameas, et al. Immunochemi s try, 1969; 6: 43. Use 4mg of the above hemocyanin peptide complex with complete Freund's adjuvant.
  • Rabbits were immunized, and 15 days later they were boosted with hemocyanin polypeptide complex and incomplete Freund's adjuvant.
  • a titer plate coated with a 15 g / ml bovine serum albumin peptide complex was used as an ELISA to determine antibody titers in rabbit serum.
  • Protein A-Sepharose was used to separate total IgG from antibody-positive rabbit sera. 0
  • the peptide was bound to a cyanogen bromide-activated Sepharose4B column, and anti-peptide antibodies were isolated from the total IgG by affinity chromatography.
  • the immunoprecipitation method proved that the purified antibody could specifically bind to the human L1 element class ORF2 protein 21.
  • Example 7 Application of the polynucleotide fragment of the present invention as a hybridization probe
  • Suitable oligonucleotide fragments selected from the polynucleotides of the present invention are used as hybridization probes in a variety of ways.
  • the probes can be used to hybridize to genomic or cDNA libraries of normal tissue or pathological tissue from different sources to It is determined whether it contains the polynucleotide sequence of the present invention and a homologous polynucleotide sequence is detected.
  • the probe can be used to detect the polynucleotide sequence of the present invention or its homologous polynucleotide sequence in normal tissue or pathology. Whether the expression in tissue cells is abnormal.
  • the purpose of this embodiment is to select a suitable oligonucleotide fragment from the polynucleotide SEQ ID NO: 1 of the present invention as a hybridization probe, and to identify whether some tissues contain the polynucleoside of the present invention by a filter hybridization method Acid sequence or a homologous polynucleotide sequence thereof.
  • Filter hybridization methods include dot blotting, Southern imprinting, Northern blotting, and copying methods. They all use the same steps to immobilize the polynucleotide sample to be tested on the filter.
  • the sample-immobilized filter is first pre-hybridized with a probe-free hybridization buffer to saturate the non-specific binding site of the sample on the filter with the carrier and the synthesized polymer. Then, the pre-hybridization solution is replaced with a hybridization buffer containing the labeled probe, and the incubation is performed to hybridize the probe to the target nucleic acid. After the hybridization step, the unhybridized probes are removed by a series of membrane washing steps. This embodiment uses higher-intensity washing conditions (such as lower salt concentration and higher temperature), so that the hybridization background is reduced and only strong specific signals are retained.
  • higher-intensity washing conditions such as lower salt concentration and higher temperature
  • the probes used in this embodiment include two types: the first type of probes are oligonucleotide fragments that are completely the same as or complementary to the polynucleotide SEQ ID NO: 1 of the present invention; the second type of probes are partially related to the present invention
  • the polynucleotide SEQ ID NO: 1 is the same or complementary oligonucleotide fragment.
  • the dot blot method is used to fix the sample on the filter membrane. Under the high-intensity washing conditions, the first type of probe and the sample have the strongest hybridization specificity and are retained.
  • the preferred range of probe size is 18-50 nucleotides
  • Those that meet the above conditions can be used as primary selection probes, and then further computer sequence analysis, including the primary selection probe and its source sequence region (ie, SEQ ID NO: 1) and other known genomic sequences and their complements The regions are compared for homology. If the homology with the non-target molecular region is greater than 85% or there are more than 15 consecutive bases, the primary probe should not be used;
  • Probe 1 which belongs to the first type of probe, is completely homologous or complementary to the gene fragment of SEQ ID NO: 1 (41Nt):
  • Probe 2 (probe2), which belongs to the second type of probe, is equivalent to the replacement mutant sequence of the gene fragment of SEQ ID NO: 1 or its complementary fragment (41Nt):
  • PBS phosphate buffered saline
  • DNA phenol extraction method Steps: 1) Wash cells with 1-10 ml of cold PBS and centrifuge at 1000 g for 10 minutes. 2) Resuspend the pelleted cells with cold cell lysate (lx 10 8 cells / ml) with a minimum of 100ui lysis buffer. 3) Add SDS to a final concentration of 1%. If SDS is directly added to the cell pellet before resuspending the cells, the cells may form large clumps that are difficult to break, and reduce the overall yield. This is particularly serious when extracting> 10 7 cells. 4) Add proteinase K to a final concentration of 200ug / ml. 5) Incubate at 50 ° C for 1 hour or shake gently at 37 ° C overnight.
  • step 8-13 are only used when contamination must be removed, otherwise step 14 can be performed directly.
  • NC membranes nitrocellulose membranes
  • Two NC membranes are required for each probe, so as to be used in the following experimental steps.
  • the film was washed with high-strength conditions and strength conditions, respectively.
  • pre-hybridization solution 10xDenhardt's; 6xSSC, 0.1 mg / ml CT DNA (calf thymus DNA).
  • X-ray auto-development -70 ° C
  • X-ray autoradiography press time depends on the radioactivity of the hybrid spot
  • polypeptide of the present invention and the antagonists, agonists and inhibitors of the polypeptide can be directly used in the treatment of diseases, for example, it can treat malignant tumors, adrenal deficiency, skin diseases, various inflammations, HIV infections and immune diseases.
  • LINEs are members of a family that intersperses long sequences in the human genome.
  • Human long-dispersed repeats LINE-1 (L1) constitute a highly repetitive DNA family.
  • the expression of the L1 transcription factor is relatively human-specific and is important for cell proliferation.
  • Recently, a new LINE1 transcription factor has been found in small cell lung cancer. The nucleotide sequence of this factor is consistent with the entire open reading frame of 6.5kb L1 2
  • L1 element class 0RF2 protein (01 ⁇ 2) has a similarity of 98.4%, so it is called an L1 element class 0RF2 protein. This protein is important for cell proliferation. Abnormal expression in vivo can affect the body's regulation of cell proliferation, which in turn leads to embryonic developmental disorders, autoimmune diseases, and tumor diseases.
  • the polypeptide of the present invention and the human L1 element class 0RF2 protein are human L1 element class 0RF2 proteins and contain characteristic sequences of the LINE-1 (L1) family. Both have similar biological functions.
  • the abnormal expression of the polypeptide in vivo can affect The body's regulation of cell proliferation leads to the development of embryonic disorders, autoimmune diseases, and tumor diseases. These diseases include, but are not limited to:
  • Chronic non-specific ulcerative colitis chronic active hepatitis, malignant anemia, atrophic gastritis; five.
  • Urinary system diseases Autoimmune glomerulonephritis, pulmonary and renal hemorrhagic syndrome, etc .;
  • Cleft lip (most common, with alveolar cleft and cleft palate), cleft lip, facial oblique cleft, cervical pouch, cervical fistula, etc.
  • Absent in longitudinal direction Absence of upper limb radius / ulnar side, lower limb tibia / fibula, etc .;
  • Limb differentiation disorder Absence of a certain muscle or muscle group, joint dysplasia, bone deformity, bone fusion, multi-finger (toe) deformity, and (toe) malformation, horse tellurium varus, etc .;
  • Thyroglossal duct cysts atresia or stenosis of the digestive tract, ileal diverticulum, umbilical fistula, congenital umbilical hernia, congenital agangliomegalo colon, impotence of anus, abnormal bowel transition, bile duct atresia, circular pancreas, etc
  • neural tube defects no cerebral malformations, spina bifida, spinal meningocele, hydrocephalous meningoencephalocele
  • hydrocephalus inside / outside the brain, etc.
  • Epithelial tissue Papilloma, squamous cell carcinoma [skin, nasopharynx, larynx, cervix], adenoma (carcinoma) [breast, thyroid], mucinous / serous cystadenomas (carcinoma) [ovarian], basal cell carcinoma [head and facial skin ] (Malignant) polytype adenoma [extending gland], papilloma, transitional epithelial cancer [bladder, renal pelvis], etc .; 2.
  • Mesenchymal tissue Papilloma, squamous cell carcinoma [skin, nasopharynx, larynx, cervix], adenoma (carcinoma) [breast, thyroid], mucinous / serous cystadenomas (carcinoma) [ovarian], basal cell carcinoma [head and facial skin ] (Malignant) polytype adenoma [extending gland], pap
  • Malignant lymphoma [Neck, mediastinum, mesenteric and retroperitoneal lymph nodes], various leukemias [lymphoid hematopoietic tissue], multiple myeloma [push / thoracic / rib / skull and long bone], etc .;
  • Nerve fiber [systemic cutaneous nerve / deep nerve and internal organs], (malignant) schwannoma [nervous of head, neck, limbs, etc.], (malignant) glioblastoma [brain], medulloblastoma [ Cerebellum], (malignant) meningiomas [meninges], ganglioblastoma / neuroblastoma [mediastinum and retroperitoneum / adrenal medulla], etc .;
  • malignant melanoma [skin, mucosa], (malignant) hydatidiform mole, chorionic epithelial cancer [uterine], (malignant) supporter cells, stromal cell tumor, (malignant) granulosa cell tumor [ovary, testis], fine Blastoma [testis], asexual cell tumor [ovary], embryonal cancer [testis, ovary], (malignant) teratoma [ovary, testis, mediastinum and palate tail], etc .;
  • polypeptide of the present invention and the antagonist, agonist and inhibitor of the polypeptide can be directly used for the treatment of various diseases, such as embryonic developmental disorders, autoimmune diseases, and tumor diseases.
  • the invention also provides methods for screening compounds to identify agents that increase (agonist) or suppress (antagonist) human L1 element orf2 protein 21.
  • Agonists enhance human L1 element class 0RF2 protein 21 to stimulate biological functions such as cell proliferation, while antagonists prevent and treat disorders related to excessive cell proliferation, such as various cancers.
  • a mammalian cell or a membrane preparation expressing human L1 element class 0RF2 protein 21 can be cultured with a labeled human L1 element class 0RF2 protein 21 in the presence of a drug. The ability of the drug to increase or block this interaction is then determined.
  • Antagonists of human L1 element class 0RF2 protein 21 include antibodies, compounds and receptor deletions And similar. Antagonists of human L1 element class 0RF2 protein 21 can bind to human L1 element class 0RF2 protein 21 and eliminate its function, or inhibit the production of the polypeptide, or bind to the active site of the polypeptide so that the polypeptide cannot exert biology Features.
  • human L1 element class 0RF2 protein 21 can be added to a bioanalytical assay to determine whether a compound is a compound by measuring the effect of the compound on the interaction between human L1 element class 0RF2 protein 21 and its receptor. Antagonist. Receptor deletions and analogs that act as antagonists can be screened in the same way as for screening compounds described above.
  • Polypeptide molecules capable of binding to human L1 element class 0RF2 protein 21 can be obtained by screening a random peptide library composed of various possible combinations of amino acids bound to a solid phase. In the screening, 21 molecules of the human L1 element class 0RF2 protein should generally be labeled.
  • the present invention provides a method for producing antibodies using polypeptides, and fragments, derivatives, analogs or cells thereof as antigens. These antibodies can be polyclonal or monoclonal antibodies.
  • the invention also provides antibodies directed against the human L1 element class ORF2 protein 21 epitope. These antibodies include (but are not limited to): polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments, and fragments generated from Fab expression libraries.
  • Polyclonal antibodies can be produced by injecting human L1 element class 0RF2 protein 21 directly into immunized animals (such as rabbits, mice, rats, etc.).
  • immunized animals such as rabbits, mice, rats, etc.
  • a variety of adjuvants can be used to enhance the immune response, including but not limited to Freund's Agent.
  • Techniques for preparing monoclonal antibodies to human L1 element class RFF2 protein 21 include, but are not limited to, hybridoma technology (Kohler and Miste in. Nature, 1975, 256: 495-497), triple tumor technology, human beta cells Hybridoma technology, EBV-hybridoma technology, etc.
  • Chimeric antibodies that bind human constant regions to non-human-derived variable regions can be produced using existing techniques (Morrison et al., PNAS, 1985, 81: 6851).
  • the existing technology for producing single chain antibodies (U.S. Pat No. 4946778) can also be used to produce single chain antibodies against human L1 element 0RF2 protein 21.
  • Antibodies against human L1 element class 0RF2 protein 21 can be used in immunohistochemistry to detect human L1 element class 0RF2 protein 21 in biopsy specimens.
  • Monoclonal antibodies that bind to human L1 element class 0RF2 protein 21 can also be labeled with radioisotopes and injected into the body to track their location and distribution. This radiolabeled antibody can be used as a non-invasive diagnostic method to locate tumor cells and determine whether there is metastasis.
  • Antibodies can also be used to design immunotoxins that target a particular part of the body.
  • human L1 element class RFF2 protein 21 high affinity monoclonal antibody can covalently bind to bacterial or plant toxins (such as diphtheria toxin, ricin, ormosine, etc.).
  • a common method is to attack the amino group of an antibody with a thiol cross-linking agent such as SPDP and bind the toxin to the antibody through the exchange of disulfide bonds.
  • This hybrid antibody can be used to kill human L1 element class 0RF2 protein 21 positive cell.
  • the antibodies in the present invention can be used to treat or prevent diseases related to the human LI element type ORF2 protein 21. Administration of an appropriate dose of the antibody can stimulate or block the production or activity of the human L1 element class ORF2 protein 21.
  • the present invention also relates to a diagnostic test method for quantitatively and locally detecting the level of human L1 element type RFF2 protein 21.
  • tests are well known in the art and include FI SH assays and radioimmunoassays.
  • the level of human L1 element class 0RF2 protein 21 detected in the test can be used to explain the importance of human L1 element class 0RF2 protein 21 in various diseases and to diagnose diseases in which human L1 element class 0RF2 protein 21 plays a role.
  • polypeptide of the present invention can also be used for peptide mapping analysis.
  • the polypeptide can be specifically cleaved by physical, chemical or enzymatic analysis, and subjected to one-dimensional or two-dimensional or three-dimensional gel electrophoresis analysis, and more preferably mass spectrometry analysis.
  • Polynucleotides encoding the human L1 element class ORF2 protein 21 can also be used for a variety of therapeutic purposes. Gene therapy technology can be used to treat abnormal cell proliferation, development or metabolism caused by the non-expression or abnormal / inactive expression of human L1 element class 0RF2 protein 21.
  • Recombinant gene therapy vectors (such as viral vectors) can be designed to express variant human L1 element class 0RF2 protein 21 to inhibit endogenous human L1 element class 0RF2 protein 21 activity.
  • a variant human L1 element class 0RF2 protein 21 may be shortened and lack human signaling element domain ORF2 protein 21, and although it can bind to downstream substrates, it lacks signal transduction activity.
  • the recombinant gene therapy vector can be used to treat diseases caused by abnormal expression or activity of human L1 element class 0RF2 protein 21.
  • Virus-derived expression vectors such as retrovirus, adenovirus, adenovirus-associated virus, herpes simplex virus, parvovirus and the like can be used to transfer a polynucleotide encoding human L1 element class 0RF2 protein 21 into cells.
  • a method for constructing a recombinant viral vector carrying a polynucleotide encoding the human L1 element class ORF2 protein 21 can be found in the existing literature (Sambrook, et al.).
  • a polynucleotide encoding the human L1 element class 0RF2 protein 21 can be packaged into liposomes and transferred into cells.
  • Methods for introducing a polynucleotide into a tissue or cell include: directly injecting the polynucleotide into a tissue in vivo; or introducing the polynucleotide into a cell in vitro through a vector (such as a virus, phage, or plasmid), and then transplanting the cell Into the body and so on.
  • a vector such as a virus, phage, or plasmid
  • Oligonucleotides including antisense RNA and DNA
  • ribozymes that inhibit the human L1 element class 0RF2 protein 21 mRNA are also within the scope of the present invention.
  • a ribozyme is an enzyme-like RNA molecule that can specifically decompose a specific RM. Its mechanism of action is that the ribozyme molecule specifically hybridizes with a complementary target RNA and performs endonucleation.
  • Antisense RNA, DNA, and ribozymes can be obtained by any existing RNA or DNA synthesis technology, such as the technology for the synthesis of oligonucleotides by solid-phase phosphoramidite chemical synthesis, which is widely used.
  • Antisense RNA molecules can be obtained by in vitro or in vivo transcription of a DNA sequence encoding the RNA. This DM sequence has been integrated downstream of the vector's RNA polymerase promoter. To increase the stability of nucleic acid molecules, they can be modified in a variety of ways. For example, if the sequence length on both sides is increased, the linkage between ribonucleosides should use phosphorothioate or peptide bonds instead of phosphodiester bonds.
  • the polynucleotide encoding human L1 element class 0RF2 protein 21 can be used for diagnosis of diseases related to human L1 element class 0RF2 protein 21.
  • the polynucleotide encoding human L1 element class 0RF2 protein 21 can be used to detect the expression of human L1 element class 0RF2 protein 21 or the abnormal expression of human L1 element class 0RF2 protein 21 in a disease state.
  • the DNA sequence encoding the human L1 element class 0RF2 protein 21 can be used to hybridize biopsy specimens to determine the expression status of the human L1 element class 0RF2 protein 21.
  • Hybridization techniques include Sou thern blotting, Nor thern blotting, and in situ hybridization.
  • Some or all of the polynucleotides of the present invention can be used as probes to be fixed on a microarray (Mi croar ray) or a DNA chip (also known as a "gene chip"), and used to analyze differential expression analysis of genes and genetic diagnosis in tissues.
  • Human L1 element class 0RF2 protein 21-specific primers can be used for RNA-polymerase chain reaction (RT-PCR) in vitro amplification to detect the transcription products of human L1 element class 0RF2 protein 21.
  • Human L1 element class 0RF2 protein 21 mutations include point mutations, translocations, deletions, recombinations, and any other abnormalities compared to the normal wild-type human L1 element class 0RF2 protein 21 DNA sequence. Mutations can be detected using existing techniques such as Southern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, mutations may affect protein expression. Therefore, Nor thern blotting and Western blotting can be used to indirectly determine whether a gene is mutated.
  • the sequences of the invention are also valuable for chromosome identification.
  • the sequence specifically targets a specific position on a human chromosome and can hybridize to it.
  • an important first step is to locate these DM sequences on a chromosome.
  • PCR primers (preferably 1 to 35 bp) are prepared based on the cDNA, and the sequences can be located on the chromosomes. These primers were then used for PCR screening of somatic hybrid cells containing individual human chromosomes. Only those hybrid cells that have a human gene corresponding to the primer will produce amplified fragments.
  • PCR localization of somatic hybrid cells is a quick way to localize DNA to specific chromosomes.
  • oligonucleotide primers of the present invention by a similar method, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization.
  • Other similar strategies that can be used for chromosomal localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and hybrid pre-selection to construct chromosome-specific cDNA libraries.
  • Fluorescent in situ hybridization (FISH) of cDNA clones to metaphase chromosomes allows precise chromosomal localization in one step.
  • FISH fluorescent in situ hybridization
  • the physical location of the sequence on the chromosome can be correlated with the genetic map data. These data can be found in, for example, V. Mckusick, Mende l ian
  • the difference in cDNA or genomic sequence between the affected and unaffected individuals needs to be determined. If a mutation is observed in some or all of the affected individuals and the mutation is not observed in any normal individual, the mutation may be the cause of the disease. Comparing affected and unaffected individuals usually involves first looking for structural changes in chromosomes, such as deletions or translocations that are visible at the chromosomal level or detectable with cDNA sequence-based PCR. According to the resolution capabilities of current physical mapping and gene mapping technology, the cDNA accurately mapped to the chromosomal region associated with the disease can be one of 50 to 500 potentially pathogenic genes (assuming 1 megabase mapping resolution) Capacity and each 20kb corresponds to a gene).
  • the polypeptides, polynucleotides and mimetics, agonists, antagonists and inhibitors of the present invention can be used in combination with a suitable pharmaceutical carrier.
  • suitable pharmaceutical carrier can be water, glucose, ethanol, salts, buffers, glycerol, and combinations thereof.
  • the composition comprises a safe and effective amount of the polypeptide or antagonist, and carriers and excipients which do not affect the effect of the drug. These compositions can be used as drugs for the treatment of diseases.
  • the invention also provides a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
  • a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
  • these containers there may be instructional instructions given by government agencies that manufacture, use, or sell pharmaceuticals or biological products, which prompts permission for administration on the human body by government agencies that produce, use, or sell.
  • the polypeptides of the invention can be used in combination with other therapeutic compounds.
  • the pharmaceutical composition can be administered in a convenient manner, such as by a topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal route of administration.
  • the human L1 element class ORF2 protein 21 is administered in an amount effective to treat and / or prevent a specific indication.
  • the amount and dose range of human L1 element class 0RF2 protein 21 administered to a patient will depend on many factors, such as the mode of administration, the health conditions of the person to be treated, and the judgment of the diagnostician.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

一种 的多肽一一人 LI元件类 0RF2蛋白 21和编码这种多肽的多核苷酸 技术领域
本发明属于生物技术领域， 具体地说， 本发明描述了一种新的多肽一一人 L1 元件类 0RF2蛋白 21 , 以及编码此多肽的多核苷酸序列。 本发明还涉及此多核 苷酸和多肽的制备方法和应用。 背景技术
主要的人类基因组由几段独特的 DM序列构成， 这些序列中散布了许多含 有重复序列的不同家族。 这些散布的重复元件可根据它们的基因组长度分类。 散布重复的短序列家族的成员， 例如 Alu重复被称为 SINEs , 而散布重复的长 序列的家族成员则被称为 LINEs。 人类长的散布重复 LINE- 1 ( L1 ) 构成了一个 高度重复的 DNA家族， 该家族缺乏长的末端重复序列。 有些 L1元件能够在哺 乳动物基因组中逆转录转座。 L1序列的特征为一个在 3'端富含 A的片段， 一个 截短的 5，端， 以及显著的长的开放阅读框 （ORFs ) 的延伸。 完整的 L1元件中 一致的序列是 6. 5kb的长度并含有两个开放阅读框 （0RF1 以及 0RF2) 。 0RF1 编码一个 40- kDa的蛋白， 而 0RF2具有一个序列上与逆转录酶一致的区域。 两 个开放阅读框区域的核苷酸序列以及两个开放阅读框的多肽链在所有的哺乳动 物细胞中都是同源的。 在许多实体瘤以及胂瘤细胞中都具有 L1转录活性。 已 有研究证实有一个对人类 L1转录十分重要的内部顺式元件以及 个与元件结 合的核因子， 这表明有些 L1家族成员是编码一个或数个保守多肽的功能基因。 L1转录的表达是相对人类特异的， 而它在细胞中的转录功能对于增殖是关键性 的 （Dombroski , B. A. , Scot t, A. F. , and Kazazian, H. H. , Jr. (1993) Proc Nat l Acad. Sci. USA 90, 6513-6517)。
近来在小细胞肺癌中发现一个新的 LINE1转录因子， 该因子的核苷酸序列 与一致完整的 6. 5kb L1中的开放阅读框 2 ( 0RF2 ) 有 98. 4%的相似性， 故而被 称为 L1元件类 0RF2蛋白。 该 L1转录因子的表达是相对人类特异的， 对于细 胞增殖十分重要， 该 L1元件类 0RF2蛋白的主要核苷酸序列与人成视网膜细胞 瘤（Rb )， IL-2以及因子 VI I I基因中的序列有高度同源性。 而 Rb以及因子 VI I I 基因在不同的癌症中具有高频率的染色体缺失， 因而基因以及染色体中广泛地 整合长的同源的 L1元件将引起异常的 DNA排列 （Kou- Wha Kuo, Harara- Ming Sheu, Yu-Sheng Huang, Biochemica l and Biophys i cal Research Communicat ions 253, 566-570 (1998) )。
本发明的新的人 L1元件类 0RF2蛋白与人 L 1元件类 0RF2蛋白在蛋白水平 上有 64%的同一性和 81%的相似性， 且亦含有 L1元件类 0RF2蛋白家族其他成 员所共有的各种特征序列片段， 两者均为 L1元件类 0RF2蛋白家族的成员， 且 具有相似的生物学功能， 故命名为人 L1元件类 0RF2蛋白 2 1。 该蛋白对于细胞 增殖十分重要， 其表达异常通常将导致异常的 DM排列， 引发各种癌症， 例如 成视网膜细胞瘤 b ) ， 小细胞肺癌等疾病。
由于如上所述人 L1元件类 0RF2蛋白 21蛋白在调节细胞分裂和胚胎发育等 机体重要功能中起重要作用， 而且相信这些调节过程中涉及大量的蛋白， 因而 本领域中一直需要鉴定更多参与这些过程的人 L1元件类 0RF2蛋白 21蛋白， 特别是鉴定这种蛋白的氨基酸序列。 新人 L1元件类 0RF2蛋白 21蛋白编码基 因的分离也为研究确定该蛋白在健康和疾病状态下的作用提供了基础。 这种蛋 白可能构成开发疾病诊断和 /或治疗药的基础， 因此分离其编码 DNA是非常重 要的。 发明的公开
本发明的一个目的是提供分离的新的多肽一一人 L1元件类 0RF2蛋白 21 以 及其片段、 类似物和衍生物。
本发明的另一个目的是提供编码该多肽的多核苷酸。
本发明的另一个目的是提供含有编码人 L1元件类 0RF2蛋白 2 1的多核苷酸 的重组载体。
本发明的另一个目的是提供含有编码人 L 1元件类 0RF2蛋白 2 1的多核苷酸 的基因工程化宿主细胞。
本发明的另一个目的是提供生产人 L1元件类 0RF2蛋白 21的方法。
本发明的另一个目的是提供针对本发明的多肽一一人 L 1元件类 0RF2蛋白 2 1 的抗体。
本发明的另一个目的是提供了针对本发明多肽一一人 L1元件类 0RF2蛋白 21 的模拟化合物、 拮抗剂、 激动剂、 抑制剂。
本发明的另一个目的是提供诊断治疗与人 L1元件类 0RF2蛋白 21异常相关 的疾病的方法。
本发明涉及一种分离的多肽， 该多肽是人源的， 它包含： 具有 SEQ ID No. 2 氨基酸序列的多肽、 或其保守性变体、 生物活性片段或衍生物。 较佳地， 该多 肽是具有 SEQ ID NO: 2氨基酸序列的多肽。
本发明还涉及一种分离的多核苷酸， 它包含选自下组的一种核苷酸序列或 其变体：
(a)编码具有 SEQ ID No. 2氨基酸序列的多肽的多核苷酸；
(b)与多核苷酸（a)互补的多核苷酸；
(c)与（a)或（b)的多核苷酸序列具有至少 70%相同性的多核苷酸。
更佳地， 该多核苷酸的序列是选自下组的一种： （a)具有 SEQ ID NO: 1 中 860- 1426位的序列； 和（b)具有 SEQ ID NO: 1中 1-1467位的序列。
本发明另外涉及一种合有本发明多核苷酸的载体， 特别是表达载体； 一种 用该载体遗传工程化的宿主细胞， 包括转化、 转导或转染的宿主细胞； 一种包 括培养所述宿主细胞和回收表达产物的制备本发明多肽的方法。
本发明还涉及一种能与本发明多肽特异性结合的抗体。
本发明还涉及一种筛选的模拟、 激活、 拮抗或抑制人 L1元件类 0RF2蛋白 21 蛋白活性的化合物的方法， 其包括利用本发明的多肽。 本发明还涉及用该方法 获得的化合物。
本发明还涉及一种体外检测与人 L1元件类 0RF2蛋白 21蛋白异常表达相关 的疾病或疾病易感性的方法， 包括检测生物样品中所述多肽或其编码多核苷酸序 列中的突变， 或者检测生物样品中本发明多肽的量或生物活性。
本发明也涉及一种药物组合物， 它含有本发明多肽或其模拟物、 激活剂、 拮 抗剂或抑制剂以及药学上可接受的载体。
本发明还涉及本发明的多肽和 /或多核苷酸在制备用于治疗癌症、 发育性 疾病或免疫性疾病或其它由于人 L1元件类 0RF2蛋白 21表达异常所引起疾病的 药物的用途。
本发明的其它方面由于本文的技术的公开， 对本领域的技术人员而言是显而 易见的。
本说明书和权利要求书中使用的下列术语除非特别说明具有如下的含义： "核酸序列" 是指寡核苷酸、 核苷酸或多核苷酸及其片段或部分， 也可以 指基因组或合成的 DM或 RM, 它们可以是单链或双链的， 代表有义链或反义链。 类似地， 术语 "氨基酸序列" 是指寡肽、 肽、 多肽或蛋白质序列及其片段或部 分。 当本发明中的 "氨基酸序列" 涉及一种天然存在的蛋白质分子的氨基酸序 列时， 这种 "多肽" 或 "蛋白质" 不意味着将氨基酸序列限制为与所述蛋白质 分子相关的完整的天然氨基酸。 蛋白质或多核苷酸 "变体" 是指一种具有一个或多个氨基酸或核苷酸改变 的氨基酸序列或编码它的多核苷酸序列。 所述改变可包括氨基酸序列或核苷酸 序列中氨基酸或核苷酸的缺失、 插入或替换。 变体可具有 "保守性" 改变， 其 中替换的氨基酸具有与原氨基酸相类似的结构或化学性质， 如用亮氨酸替换异 亮氨酸。 变体也可具有非保守性改变， 如用色氨酸替换甘氨酸。
"缺失" 是指在氨基酸序列或核苷酸序列中一个或多个氨基酸或核苷酸的 缺失。
"插入" 或 "添加" 是指在氨基酸序列或核苷酸序列中的改变导致与天然存在 的分子相比， 一个或多个氨基酸或核苷酸的增加。 "替换 " 是指由不同的氨基酸或 核苷酸替换一个或多个氨基酸或核苷酸。
"生物活性" 是指具有天然分子的结构、 调控或生物化学功能的蛋白质。 类似 地， 术语 "免疫学活性" 是指天然的、 重组的或合成蛋白质及其片段在合适的动 物或细胞中诱导特定免疫反应以及与特异性抗体结合的能力。
"激动剂" 是指当与人 L1元件类 0RF2蛋白 21结合时， 一种可引起该蛋白质 改变从而调节该蛋白质活性的分子。 激动剂可以包括蛋白质、 核酸、 碳水化合 物或任何其它可结合人 L1元件类 0RF2蛋白 21的分子。
"拮抗剂" 或 "抑制物" 是指当与人 L1元件类 0RF2蛋白 21结合时， 一种可 封闭或调节人 L1元件类 0RF2蛋白 21的生物学活性或免疫学活性的分子。 拮抗剂 和抑制物可以包括蛋白质、核酸、碳水化合物或任何其它可结合人 L1元件类 0RF2 蛋白 21的分子。
"调节" 是指人 L1元件类 0RF2蛋白 21的功能发生改变， 包括蛋白质活性的 升高或降低、 结合特性的改变及人 L1元件类 0RF2蛋白 21的任何其它生物学性 质、 功能或免疫性质的改变。
"基本上纯' '是指基本上不含天然与其相关的其它蛋白、脂类、糖类或其它物质。 本领域的技术人员能用标准的蛋白质纯化技术纯化人 L1 元件类 0RF2 蛋白 21。 基 本上纯的人 L1元件类 0RF2蛋白 21在非还原性聚丙烯酰胺凝胶上能产生单一的主 带。 人 L1元件类 0RF2蛋白 21多肽的纯度可用氨基酸序列分析。
"互补的" 或 "互补" 是指在允许的盐浓度和温度条件下通过碱基配对的 多核苷酸天然结合。 例如， 序列 "C- T- G- A" 可与互补的序列 "G- A- C- T" 结合。 两个单链分子之间的互补可以是部分的或全部的。 核酸链之间的互补程度对于 核酸链之间杂交的效率及强度有明显影响。
"同源性" 是指互补的程度， 可以是部分同源或完全同源。 "部分同源" 是指一种部分互补的序列， 其至少可部分抑制完全互补的序列与靶核酸的杂 交。 这种杂交的抑制可通过在严格性程度降低的条件下进行杂交 （Southern印 迹或 Nor thern印迹等） 来检测。 基本上同源的序列或杂交探针可竟争和抑制完 全同源的序列与靶序列在的严格性程度降低的条件下的结合。 这并不意味严格 性程度降低的条件允许非特异性结合， 因为严格性程度降低的条件要求两条序 列相互的结合为特异性或选择性相互作用。
"相同性百分率" 是指在两种或多种氨基酸或核酸序列比较中序列相同或 相似的百分率。 可用电子方法测定相同性百分率， 如通过 MEGALIGN程序
( Lasergene sof tware package, DNASTAR, Inc. , Madi son Wi s. ) 。 MEGALIGN 程序可根据不同的方法如 Clus ter法比较两种或多种序列（Hi gg ins, D. G, 和 P. M. Sharp (1988) Gene 73: 237-244) 0 Clus ter法通过检查所有配对之间的距 离将各组序列排列成簇。 然后将各簇以成对或成组分配。 两个氨基酸序列如序 列 A和序列 B之间的相同性百分率通过下式计算： 序列 A与序列 B之间匹配的残基个数 X 100 序列 A的残基数一序列 A中间隔残基数一序列 B中间隔残基数 也可以通过 Clus ter法或用本领域周知的方法如 Jotun Hein 测定核酸序列 之间的相同性百分率（Hein J. , (1990) Methods in emzumology 183: 625-645) 0 "相似性" 是指氨基酸序列之间排列对比时相应位置氨基酸残基的相同或 保守性取代的程度。 用于保守性取代的氨基酸例如， 带负电荷的氨基酸可包括 天冬氨酸和谷氨酸； 带正电荷的氨基酸可包括赖氨酸和精氨酸； 具有不带电荷 的头部基团有相似亲水性的氨基酸可包括亮氨酸、 异亮氨酸和缬氨酸； 甘氨酸 和丙氨酸； 天冬酰胺和谷氨酰胺； 丝氨酸和苏氨酸； 苯丙氨酸和酪氨酸。
"反义" 是指与特定的 DNA或 RNA序列互补的核苷酸序列。 "反义链" 是指 与 "有义链" 互补的核酸链。
"衍生物" 是指 HFP或编码其的核酸的化学修饰物。 这种化学修饰物可以是 用垸基、 酰基或氨基替换氢原子。 核酸衍生物可编码保留天然分子的主要生物 学特性的多肽。
"抗体" 是指完整的抗体分子及其片段， 如 Fa、 ？（&1)') 2及？ , 其能特异 性结合人 L1元件类 0RF2蛋白 21的抗原决定簇。 "人源化抗体" 是指非抗原结合区域的氨基酸序列被替换变得与人抗体更 为相似， 但仍保留原始结合活性的抗体。
"分离的" 一词指将物质从它原来的环境 （例如， 若是自然产生的就指其 天然环境） 之中移出。 比如说， 一个自然产生的多核苷酸或多肽存在于活动物 中就是没有被分离出来， 但同样的多核苷酸或多肽同一些或全部在自然系统中 与之共存的物质分开就是分离的。 这样的多核苷酸可能是某一载体的一部分， 也可能这样的多核苷酸或多肽是某一组合物的一部分。 既然载体或组合物不是 它天然环境的成分， 它们仍然是分离的。
如本发明所用， "分离的" 是指物质从其原始环境中分离出来 （如果是天 然的物质， 原始环境即是天然环境） 。 如活体细胞内的天然状态下的多聚核苷 酸和多肽是没有分离纯化的， 但同样的多聚核苷酸或多肽如从天然状态中同存 在的其他物质中分开， 则为分离纯化的。
如本文所用， "分离的人 L1元件类 0RF2蛋白 21" 是指人 L1元件类 0RF2 蛋白 21基本上不含天然与其相关的其它蛋白、 脂类、 糖类或其它物质。 本领域 的技术人员能用标准的蛋白质纯化技术纯化人 L1元件类 0RF2蛋白 21。 基本上 纯的多肽在非还原聚丙烯酰胺凝胶上能产生单一的主带。 人 L1元件类 0RF2蛋 白 21多肽的纯度能用氨基酸序列分析。
本发明提供了一种新的多肽一一人 L1元件类 0RF2蛋白 21，其基本上是由 SEQ ID NO: 2所示的氨基酸序列组成的。 本发明的多肽可以是重组多肽、 天然多肽、 合成 多肽， 优选重组多肽。 本发明的多肽可以是天然纯化的产物， 或是化学合成的产 物， 或使用重组技术从原核或真核宿主 (例如， 细菌、 酵母、 高等植物、 昆虫和哺 乳动物细胞）中产生。 根据重组生产方案所用的宿主， 本发明的多肽可以是糖基化 的， 或可以是非糖基化的。 本发明的多肽还可包括或不包括起始的甲硫氨酸残基。
本发明还包括人 L1元件类 0RF2蛋白 21的片段、 衍生物和类似物。 如本 发明所用， 术语 "片段" 、 "衍生物" 和 "类似物" 是指基本上保持本发明的 人 L1元件类 0RF2蛋白 21相同的生物学功能或活性的多肽。 本发明多肽的片 段、 衍生物或类似物可以是： U ) 这样一种， 其中一个或多个氨基酸残基被 保守或非保守氨基酸残基 （优选的是保守氨基酸残基） 取代， 并且取代的氨基 酸可以是也可以不是由遗传密码子编码的； 或者 （ Π ) 这样一种， 其中一个或 多个氨基酸残基上的某个基团被其它基团取代包含取代基； 或者 （I I I ) 这样 一种， 其中成熟多肽与另一种化合物 （比如延长多肽半衰期的化合物， 例如聚 乙二醇） 融合； 或者 （ IV ) 这样一种， 其中附加的氨基酸序列融合进成熟多肽 而形成的多肽序列 （如前导序列或分泌序列或用来纯化此多肽的序列或蛋白原 序列） 通过本文的阐述， 这样的片段、 衍生物和类似物被认为在本领域技术人 员的知识范围之内。
本发明提供了分离的核酸 （多核苷酸） ， 基本由编码具有 SEQ ID NO: 2 氨 基酸序列的多肽的多核苷酸组成。 本发明的多核苷酸序列包括 SBQ ID NO: 1的 核苷酸序列。 本发明的多核苷酸是从人胎脑组织的 cDNA文库中发现的。 它包 含的多核苷酸序列全长为 1467个碱基， 其开放读框 860- 1426编码了 1 88个氨 基酸。 根据氨基酸序列同源比较发现， 此多肽与人 L1元件类 0RF2蛋白有 64% 的同源性， 可推断出该人 L1元件类 0RF2蛋白 21具有人 L1元件类 0RF2蛋白 相似的结构和功能。
本发明的多核苷酸可以是 DNA形式或是 MA形式。 DNA形式包括 cDNA、 基 因组 DNA或人工合成的 DNA。 DNA可以是单链的或是双链的。 DNA可以是编码链 或非编码链。 编码成熟多肽的编码区序列可以与 SEQ ID NO: 1所示的编码区序 列相同或者是简并的变异体。 如本发明所用， "简并的变异体" 在本发明中是 指编码具有 SEQ ID NO: 2的蛋白质或多肽， 但与 SEQ ID NO: 1所示的编码区序 列有差别的核酸序列。
编码 SEQ ID NO: 2的成熟多肽的多核苷酸包括： 只有成熟多肽的编码序列; 成熟多肽的编码序列和各种附加编码序列； 成熟多肽的编码序列 （和任选的附 加编码序列） 以及非编码序列。
术语 "编码多肽的多核苷酸" 是指包括编码此多肽的多核苷酸和包括附加 编码和 /或非编码序列的多核苷酸。
本发明还涉及上述描述多核苷酸的变异体， 其编码与本发明有相同的氨基 酸序列的多肽或多肽的片断、 类似物和衍生物。 此多核苷酸的变异体可以是天 然发生的等位变异体或非天然发生的变异体。 这些核苷酸变异体包括取代变异 体、 缺失变异体和插入变异体。 如本领域所知的， 等位变异体是一个多核苷酸 的替换形式， 它可能是一个或多个核苷酸的取代、 缺失或插入， 但不会从实质 上改变其编码的多肽的功能。
本发明还涉及与以上所描述的序列杂交的多核苷酸 （两个序列之间具有至 少 50% , 优选具有 70%的相同性） 。 本发明特别涉及在严格条件下与本发明所 述多核苷酸可杂交的多核苷酸。 在本发明中， "严格条件" 是指： （1)在较低 离子强度和较高温度下的杂交和洗脱， 如 0. 2xSSC, 0. 1 /。SDS, 6 (TC ;或（2)杂交 时加用变性剂， 如 50% (v/v)甲酰胺， 0. 1%小牛血清 / 0. l%Fi co l l , 42 °C等； 或（3) 仅在两条序列之间的相同性至少在 95%以上，更好是 97%以上时才发生杂交。 并 且， 可杂交的多核苷酸编码的多肽与 SEQ ID NO: 2所示的成熟多肽有相同的 生物学功能和活性。
本发明还涉及与以上所描述的序列杂交的核酸片段。 如本发明所用， "核 酸片段"的长度至少含 10个核苷酸， 较好是至少 20- 30个核苷酸， 更好是至少 50 - 60个核苷酸， 最好是至少 100个核苷酸以上。 核酸片段也可用于核酸的扩 增技术（如 PCR)以确定和 /或分离编码人 L1元件类 0RF2蛋白 21的多核苷酸。
本发明中的多肽和多核苷酸优选以分离的形式提供， 更佳地被纯化至均质。 本发明的编码人 L1元件类 0RF2蛋白 21的特异的多核苷酸序列能用多种方 法获得。 例如， 用本领域熟知的杂交技术分离多核苷酸。 这些技术包括但不局 限于： 1)用探针与基因组或 cDNA文库杂交以检出同源的多核苷酸序列， 和 2) 表达文库的抗体筛选以检出具有共同结构特征的克隆的多核苷酸片段。
本发明的 DM片段序列也能用下列方法获得： 1)从基因组 DNA分离双链 DNA 序列； 2)化学合成 DNA序列以获得所述多肽的双链 DNA。
上述提到的方法中， 分离基因组 DNA最不常用。 DNA序列的直接化学合成 是经常选用的方法。 更经常选用的方法是 cDNA序列的分离。 分离感兴趣的 cDNA 的标准方法是从高表达该基因的供体细胞分离 mRNA并进行逆转录， 形成质粒或 噬菌体 cDNA文库。 提取 mRNA的方法已有多种成熟的技术， 试剂盒也可从商业 途径获得（Q i agene)。 而构建 cDNA文库也是通常的方法（Sambrook, e t a l. , Mol ecu l ar Cl oning, A Labora tory Manua l , Co ld Spr ing Harbor Labora tory. New York , 1989)„ 还可得到商业供应的 cDNA文库， 如 C l ontech公司的不同 cDNA 文库。 当结合使用聚合酶反应技术时， 即使极少的表达产物也能克隆。
可用常规方法从这些 cDM文库中筛选本发明的基因。 这些方法包括（但不 限于）： （l) DNA-DNA或 DM- RM杂交； （2)标志基因功能的出现或丧失； （3)测定 人 L1元件类 0RF2蛋白 21的转录本的水平； （4)通过免疫学技术或测定生物学 活性， 来检测基因表达的蛋白产物。 上述方法可单用， 也可多种方法联合应用。
在第（1)种方法中， 杂交所用的探针是与本发明的多核苷酸的任何一部分同 源， 其长度至少 1 0个核苷酸， 较好是至少 30个核苷酸， 更好是至少 50个核苷 酸， 最好是至少 100个核苷酸。 此外， 探针的长度通常在 2000个核苷酸之内， 较佳的为 1000个核苷酸之内。 此处所用的探针通常是在本发明的基因序列信息 的基础上化学合成的 DNA序列。 本发明的基因本身或者片段当然可以用作探针。 DNA探针的标记可用放射性同位素， 荧光素或酶（如碱性磷酸酶）等。 在第（4)种方法中， 检测人 L1元件类 0RF2蛋白 21基因表达的蛋白产物可 用免疫学技术如 Western印迹法， 放射免疫沉淀法， 酶联免疫吸附法（ELISA)等。
应用 PCR技术扩增 DNA/RNA的方法（Saiki, et al. Science
1985; 230: 1350-1354)被优选用于获得本发明的基因。 特别是很难从文库中得到 全长的 cDNA时， 可优选使用 RACE法（RACE- cDM末端快速扩增法）， 用于 PCR 的引物可根据本文所公开的本发明的多核苷酸序列信息适当地选择， 并可用常 规方法合成。 可用常规方法如通过凝胶电泳分离和纯化扩增的 DM/RNA片段。
如上所述得到的本发明的基因， 或者各种 DNA片段等的多核苷酸序列可用 常规方法如双脱氧链终止法（Sanger et al. PNAS, 1977, 74： 5463- 5467)测定。 这类多核苷酸序列测定也可用商业测序试剂盒等。为了获得全长的 cDNA序列， 测 序需反复进行。 有时需要测定多个克隆的 cMA序列， 才能拼接成全长的 cDNA 序列。
本发明也涉及包含本发明的多核苷酸的载体， 以及用本发明的载体或直接 用人 L1元件类 0RF2蛋白 21编码序列经基因工程产生的宿主细胞， 以及经重组 技术产生本发明所述多肽的方法。
本发明中，编码人 L1元件类 0RF2蛋白 21的多核苷酸序列可插入到载体中， 以构成含有本发明所述多核苷酸的重组载体。 术语 "载体" 指本领域熟知的细 菌质粒、 噬菌体、 酵母质粒、 植物细胞病毒、 哺乳动物细胞病毒如腺病毒、 逆 转录病毒或其它载体。 在本发明中适用的载体包括但不限于： 在细菌中表达的 基于 T7启动子的表达载体（Rosenberg, et al. Gene, 1987, 56: 125)； 在哺乳 动物细胞中表达的 pMSXND表达载体（Lee and Nathans, J Bio Chem.
263: 3521, 1988)和在昆虫细胞中表达的来源于杆状病毒的载体。 总之， 只要能 在宿主体内复制和稳定， 任何质粒和载体都可以用于构建重组表达载体。 表达 载体的一个重要特征是通常含有复制起始点、 启动子、 标记基因和翻译调控元 件。
本领域的技术人员熟知的方法能用于构建含编码人 L1元件类 0RF2蛋白 21 的 DNA序列和合适的转录 /翻译调控元件的表达载体。这些方法包括体外重组 DNA 技术、 DNA合成技术、 体内重组技术等（Sambroook, et al. Molecular Cloning, ■ a Laboratory Manual, cold Spring Harbor Laboratory. New York, 1989)。
所述的 DNA序列可有效连接到表达载体中的适当启动子上， 以指导 mRNA合成。 这些启动子的代表性例子有： 大肠杆菌的 lac或 trp启动子； λ噬菌体的 PL启 动子； 真核启动子包括 CMV立即早期启动子、 HSV胸苷激酶启动子、 早期和晚 期 SV40启动子、 反转录病毒的 LTRs和其它一些巳知的可控制基因在原核细胞 或真核细胞或其病毒中表达的启动子。 表达载体还包括翻译起始用的核糖体结 合位点和转录终止子等。 在载体中插入增强子序列将会使其在高等真核细胞中 的转录得到增强。 增强子是 DNA表达的顺式作用因子， 通常大约有 1 0到 300个 碱基对， 作用于启动子以增强基因的转录。 可举的例子包括在复制起始点晚期 一侧的 1 00到 270个碱基对的 SV40增强子、 在复制起始点晚期一侧的多瘤增强 子以及腺病毒增强子等。
此外， 表达载体优选地包含一个或多个选择性标记基因， 以提供用于选择 转化的宿主细胞的表型性状， 如真核细胞培养用的二氢叶酸还原酶、 新霉素抗 性以及绿色荧光蛋白（GFP)， 或用于大肠杆菌的四环素或氨苄青霉素抗性等。
本领域一般技术人员都清楚如何选择适当的载体 /转录调控元件 （如启动 子、 增强子等） 和选择性标记基因。
本发明中， 编码人 L1元件类 0RF2蛋白 21的多核苷酸或含有该多核苷酸的 重组载体可转化或转导入宿主细胞， 以构成含有该多核苷酸或重组载体的基因 工程化宿主细胞。 术语 "宿主细胞" 指原核细胞， 如细菌细胞； 或是低等真核 细胞， 如酵母细胞； 或是高等真核细胞， 如哺乳动物细胞。 代表性例子有： 大 肠杆菌， 链霉菌属； 细菌细胞如鼠伤寒沙门氏菌； 真菌细胞如酵母； 植物细胞; 昆虫细胞如果蝇 S2或 Sf 9 ; 动物细胞如 CH0、 COS或 Bowe s黑素瘤细胞等。
用本发明所述的 DNA序列或含有所述 DNA序列的重组载体转化宿主细胞可 用本领域技术人员熟知的常规技术进行。 当宿主为原核生物如大肠杆菌时， 能 吸收 DNA的感受态细胞可在指数生长期后收获， 用（ 12法处理， 所用的步骤 在本领域众所周知。 可供选择的是用 MgC l 2。 如果需要， 转化也可用电穿孔的方 法进行。 当宿主是真核生物， 可选用如下的 DNA转染方法： 磷酸钙共沉淀法， 或者常规机械方法如显微注射、 电穿孔、 脂质体包装等。
通过常规的重组 DNA技术， 利用本发明的多核苷酸序列可用来表达或生产 重组的人 L1元件类 0RF2蛋白 21 (Sc i ence , 1984 ; 224 : 1431)。 一般来说有以 下步骤：
(1) .用本发明的编码人 人 L1元件类 0RF2蛋白 21的多核苷酸（或变异体）， 或用含有该多核苷酸的重组表达载体转化或转导合适的宿主细胞；
(2) .在合适的培养基中培养宿主细胞；
(3) .从培养基或细胞中分离、 纯化蛋白质。
在步骤 （2 ) 中， 根据所用的宿主细胞， 培养中所用的培养基可选自各种 常规培养基。 在适于宿主细胞生长的条件下进行培养。 当宿主细胞生长到适当 的细胞密度后， 用合适的方法（如温度转换或化学诱导）诱导选择的启动子， 将 细胞再培养一段时间。
在步骤 （3 ) 中， 重组多肽可包被于细胞内、 或在细胞膜上表达、 或分泌到 细胞外。 如果需要， 可利用其物理的、 化学的和其它特性通过各种分离方法分 离和纯化重组的蛋白。 这些方法是本领域技术人员所熟知的。 这些方法包括但 并不限于： 常规的复性处理、 蛋白沉淀剂处理（盐析方法）、 离心、 渗透破菌、 超声波处理、 超离心、 分子筛层析（凝胶过滤）、 吸附层析、 离子交换层析、 高 效液相层析（HPLC)和其它各种液相层析技术及这些方法的结合。 附图的简要说明
下列附图用于说明本发明的具体实施方案， 而不用于限定由权利要求书所 界定的本发明范围。
图 1是本发明人 L1元件类 0RF2蛋白 21和人 L1元件类 0RF2蛋白的氨基酸序列 同源性比较图。上方序列是人 L1元件类 0RF2蛋白 21 ,下方序列是人 L1元件类 0RF2 蛋白。 相同氨基酸在两个序列间用单字符氨基酸表示， 相似氨基酸用 "+" 表 示。
图 2 为分离的人 L1 元件类 0RF2蛋白 21 的聚丙烯酰胺凝胶电泳图 （ SDS- PAGE ) 。 21kDa为蛋白质的分子量。 箭头所指为分离出的蛋白条带。 实现本发明的最佳方式 ^ 下面结合具体实施例， 进一步阐述本发明。 应理解， 这些实施例仅用于说 明本发明而不用于限制本发明的范围。 下列实施例中未注明具体条件的实验方 法，通常按照常规条件如 Sambrook等人， 分子克隆：实验室手册（New York: Col d Spr ing Harbor Laboratory Pres s, 1989)中所述的条件， 或按照制造厂商所建 议的条件。
实施例 1 : 人 L1元件类 0RF2蛋白 21的克隆
用异硫氰酸胍 /酚 /氯仿一步法提取人胎脑总 RNA。 用 Quik mRNA Isolat ion Ki t ( Qiegene 公司产品）从总 RNA中分离 poly (A) raRNA。 2ug poly (A) mRNA经逆转录 形成 cDNA。用 Smart cDNA克隆试剂盒（购自 Clontech )将 cDNA片段定向插入到 pBSK (+) 载体 (Clontech公司产品）的多克隆位点上， 转化 DH5 c , 细菌形成 cDM文库。 用 Dye terminate cycle react ion sequencing ki t (Perkin-Elmer公司产品) 和 ABI 377 自动测序仪 (Perkin- Elmer公司）测定所有克隆的 5'和 3'末端的序列。 将测定的 cDNA 序列与已有的公共 DNA序列数据库 （Genebank )进行比较， 结果发现其中一个克隆 2448e04的 cDNA序列为新的 DNA。 通过合成一系列引物对该克隆所含的插入 cDNA片段 进行双向测定。 结果表明， 2448e04克隆所含的全长 cDNA为 1467bp (如 Seq ID NO: 1 所示） ， 从第 860bp至 1426bp有一个 567bp的开放阅读框架 （ 0RF ) , 编码一个新的 蛋白质 (如 Seq ID NO: 2所示） 。 我们将此克隆命名为 pBS- 2448e04, 编码的蛋白质 命名为人 L1元件类 0RF2蛋白 21。
实施例 2: cDNA 克隆的同源检索
将本发明的人 L1元件类 0RF2蛋白 21的序列及其编码的蛋白序列， 用 Blas t程序 (Bas icloca l Al ignment search tool) [Al t schul, SF et al.
J. Mol. Biol. 1990; 215: 403-10] , 在 Genbank、 Swissport等数据库进行同源检索。 与本发明的人 L1元件类 0RF2蛋白 21同源性最高的基因是一种已知的人 L1元件类 0RF2 蛋白， 其编码的蛋白在 Genbank的准入号为 AF003535。 蛋白质同源结果示于图 1 , 两 者高度同源， 其相同性为 64%; 相似性为 81%。
实施例 3: 用 RT-PCR方法克隆编码人 L1元件类 0RF2蛋白 21的基因
用胎脑细胞总 RNA为模板，以 ol igo-dT为引物进行逆转录反应合成 cDNA,用 Qiagene的试剂盒纯化后，用下列引物进行 PCR扩增：
Primerl: 5，一 TGACACTGTTCCTACTGAAACTAT -3' (SEQ ID NO: 3)
Primer2: 5，- CATAGGCCGAGGCGGCCGACATGT -3， (SEQ ID NO: 4)
Pr imerl为位于 SEQ ID NO: 1的 5，端的第 lbp开始的正向序列；
Pr imer2为 SEQ ID NO: 1的中的 3'端反向序列。
扩增反应的条件： 在 50 μ 1的反应体积中含有 50mmol/L KC1, 10mmol/L Tr is- Cl，（pH8. 5) , 1. 5醒 ol/L MgCl2, 200 μ mol/L dNTP, l Opmol引物， 1U的 Taq DM聚合酶 (Clontech公司产品）。 在 PE9600型 DNA热循环仪（Perkin-Elmer公司）上按下列条件 反应 25个周期: 94°C 30sec; 55。C 30sec; 72°C 2min。 在 RT- PCR时同时设 β -act in 为阳性对照和模板空白为阴性对照。 扩增产物用 QIAGEN公司的试剂盒纯化， 用 TA克 隆试剂盒连接到 pCR载体上（Invi trogen公司产品） 。 DNA序列分析结果表明 PCR产 物的 DNA序列与 SEQ ID NO: 1所示的 l-1467bp完全相同。
实施例 4: Northern 印迹法分析人 L1元件类 0RF2蛋白 21基因的表达：
用一步法提取总 RNA [Anal. Biochera 1987, 162， 156- 159]。 该法包括酸性硫氰 酸胍苯酚-氯仿抽提。 即用 4M异硫氰酸胍- 25mM柠檬酸钠， 0. 2M乙酸纳 （pH4. 0 )对 组织进行匀浆， 加入 1倍体积的苯酚和 1/5体积的氯仿-异戊醇 （49: 1 ) , 混合后离 心。 吸出水相层， 加入异丙醇 （0. 8体积） 并将混合物离心得到 RNA沉淀。 将得到的 RNA沉淀用 70%乙醇洗涤， 干燥并溶于水中。 用 20 μ § Ι ΝΑ, 在含 20mM 3- ( Ν-吗啉代） 丙磺酸（pH7. 0 ) - 5raM乙酸钠 - ImM EDTA-2. 2M甲醛的 1. 2%琼脂糖凝胶上进行电泳。 然后转移至硝酸纤维素膜上。 用 a - 32P dATP通过随机引物法制备 32P-标记的 DNA探 针。所用的 DM探针为图 1所示的 PCR扩增的人 L1元件类 0RF2蛋白 21编码区序列（860bp 至 1426bp)。 将 32P-标记的探针 (约 2 x l 06cpm/ml ) 与转移了 RNA的硝酸纤维素膜在 一溶液中于 42°C杂交过夜， 该溶液包含 50%甲酰胺 -25mM KH2P04 ( pH7. 4 ) -5 χ SSC-5 x Denhardt 's溶液和 200 y g/ml鲑精 DNA。 杂交之后， 将滤膜在 1 χ SSC- 0. 1%SDS中于 55°C洗 30min。 然后， 用 Phosphor Imager进行分析和定量。
实施例 5 : 重组人 L1元件类 0RF2蛋白 21的体外表达、 分离和纯化
根据 SEQ ID NO: 1和图 1所示的编码区序列， 设计出一对特异性扩增引物， 序 列如下：
Pr imer3: 5 '-CCCCATATGATGCTCTCTCTCGCCACTTCTATT-3 ' ( Seq ID No: 5 )
Pr imer4: 5，- CATGGATCCCTACATGAATTTAAAACTAGTTTT- 3， ( Seq ID No: 6 ) 此两段引物的 5'端分别含有 Ndel和 BamHI酶切位点， 其后分别为目的基因 5'端 和 3'端的编码序列， Ndel和 BamHI酶切位点相应于表达载体质粒 pET- 28b (+) (Novagen 公司产品， Cat. No. 69865. 3)上的选择性内切酶位点。 以含有全长目的基因的 pBS- 2448e04质粒为模板， 进行 PCR反应。 PCR反应条件为： 总体积 50 μ 1中含 pBS- 2448e04 质粒 10pg、 引物 Pr iraer-3和 Pr imer-4分另！]为 l Opmol、 Advantage polymerase Mix ( Clontech公司产品） 1 μ 1。 循环参数： 94°C 20s, 60°C 30s, 68。C 2 min，共 25个 循环。 用 Ndel和 BamHI分别对扩增产物和质粒^1"- 28 (+)进行双酶切，分别回收大片 段,并用 T4连接酶连接。 连接产物转化用氯化钙法大肠杆细菌 DH5 a，在含卡那霉素 (终浓度 3() μ §/πι1 ) 的 LB平板培养过夜后， 用菌落 PCR方法筛选阳性克隆， 并进行 测序。 挑选序列正确的阳性克隆（pET- 2448e04 )用氯化钙法将重组质粒转化大肠 杆菌 BL21 (DE3) plySs (Novagen公司产品）。 在含卡那霉素 (终浓度 30 μ g/ml ) 的 LB 液体培养基中， 宿主菌 BL21 ( pET- 2448e04 )在 37°C培养至对数生长期， 加入 IPTG 至终浓度 lmmol/L, 继续培养 5小时。 离心收集菌体， 经超声波破菌，离心收集上清， 用能与 6个组氨酸（6Hi s- Tag )结合的亲和层析柱 Hi s. Bind Quick Cartr idge( Novagen 公司产品）进行层析， 得到了纯化的目的蛋白人 L1元件类 0RF2蛋白 21。 经 SDS-PAGE 电泳， 在 2lkDa处得到一单一的条带 （图 2 ) 。 将该条带转移至 PVDF膜上用 Edams水 解法进行 N-端氨基酸序列分析， 结果 N-端 15个氨基酸与 SEQ ID NO: 2所示的 N-端 15 个氨基酸残基完全相同。 实施例 6 抗人 LI元件类 0RF2蛋白 21抗体的产生
用多肽合成仪 （PE公司产品）合成下述人 L1元件类 0RF2蛋白 21特异性的多肽： NH2-Met-Leu-Ser-Leu-Ala-Thr-Ser-I le-Gln-Hi s-Ser-Thr-Gly-Ser-Pro-C00H (SEQ ID冊：7)。 将该多肽分别与血蓝蛋白和牛血清白蛋白耦合形成复合， 方法参 见： Avrameas, et al. Immunochemi s try, 1969; 6: 43. 用 4mg上述血蓝蛋白多肽复合 物加上完全弗氏佐剂免疫家兔， 15天后再用血蓝蛋白多肽复合物加不完全弗氏佐 剂加强免疫一次。 采用经 15 g/ml牛血清白蛋白多肽复合物包被的滴定板做 ELISA 测定兔血清中抗体的滴度。 用蛋白 A - Sepharose从抗体阳性的家兔血清中分离总 IgG0 将多肽结合于溴化氰活化的 Sepharose4B柱上， 用亲和层析法从总 IgG中分离 抗多肽抗体。 免疫沉淀法证明纯化的抗体可特异性地与人 L1元件类 0RF2蛋白 21结 合。
实施例 7: 本发明的多核苷酸片段用作杂交探针的应用
从本发明的多核苷酸中挑选出合适的寡核苷酸片段用作杂交探针有多方面的 用途， 如用该探针可与不同来源的正常组织或病理组织的基因组或 cDNA文库杂交 以鉴定其是否含有本发明的多核苷酸序列和检出同源的多核苷酸序列，进一步还可 用该探针检测本发明的多核苷酸序列或其同源的多核苷酸序列在正常组织或病理 组织细胞中的表达是否异常。
本实施例的目的是从本发明的多核苷酸 SEQ ID NO: 1 中挑选出合适的寡核苷 酸片段用作杂交探针， 并用滤膜杂交方法鉴定一些组织中是否含有本发明的多核 苷酸序列或其同源的多核苷酸序列。 滤膜杂交方法包括斑点印迹法、 Southern 印 迹法、 Northern 印迹法和复印方法等， 它们都是将待测的多核苷酸样品固定在滤 膜上后使用基本相同的步骤杂交。 这些相同的步骤是： 固定了样品的滤膜首先用 不含探针的杂交缓冲液进行预杂交， 以使滤膜上样品的非特异性的结合部位被载 体和合成的多聚物所饱和。，然后预杂交液被含有标记探针的杂交缓冲液替换， 并 保温使探针与靶核酸杂交。 杂交步骤之后， 未杂交上的探针被一系列洗膜步骤除 掉。 本实施例利用较高强度的洗膜条件（如较低盐浓度和较高的温度）， 以使杂交 背景降低且只保留特异性强的信号。 本实施例选用的探针包括两类： 第一类探针 是完全与本发明的多核苷酸 SEQ ID NO: 1相同或互补的寡核苷酸片段； 第二类探 针是部分与本发明的多核苷酸 SEQ ID NO: 1相同或互补的寡核苷酸片段。 本实施 例选用斑点印迹法将样品固定在滤膜上， 在较高强度的的洗膜条件下， 第一类探 针与样品的杂交特异性最强而得以保留。
一、 探针的选用 从本发明的多核苷酸 SEQ ID NO: 1 中选择寡核苷酸片段用作杂交探针， 应遵 循以下原则和需要考虑的几个方面：
1， 探针大小优选范围为 18-50个核苷酸；
2, GC含量为 30°/»- 70%, 超过则非特异性杂交增加；
3, 探针内部应无互补区域；
4, 符合以上条件的可作为初选探针， 然后进一步作计算机序列分析， 包括将该 初选探针分别与其来源序列区域 （即 SEQ ID NO: 1) 和其它已知的基因组序列 及其互补区进行同源性比较， 若与非靶分子区域的同源性大于 85%或者有超过 15个连续碱基完全相同， 则该初选探针一般就不应该使用；
5, 初选探针是否最终选定为有实际应用价值的探针还应进一步由实验确定。
完成以上各方面的分析后挑选并合成以下二个探针：
探针 1 (probel), 属于第一类探针， 与 SEQ ID NO: 1 的基因片段完全 同源或互补 (41Nt):
5'-TGCTCTCTCTCGCCACTTCTATTCAACATAGTACTGGAAGT-3' ( SEQ ID NO: 8 )
探针 2 (probe2), 属于第二类探针， 相当于 SEQ ID NO: 1 的基因片段 或其互补片段的替换突变序列 （41Nt):
5-TGCTCTCTCTCGCCACTTCTCTTCAACATAGTACTGGAAGT-3' (SEQ ID NO: 9) 与以下具体实验步骤有关的其它未列出的常用试剂及其配制方法请参考文 献： DNA PROBES G. H. Keller; M. Μ· Manak; Stockton Press, 1989 (USA)以及更常 用的分子克隆实验手册书籍如 《分子克隆实验指南》（ 1998 年第二版） [美]萨姆 布鲁克等著， 科学出版社。
样品制备：
1, 从新鲜或冰冻组织中提取 DM
步骤： 1) 将新鲜或新鲜解冻的正常肝组织放入浸在冰上并盛有磷酸盐缓冲液 (PBS) 的平皿中。 用剪刀或手术刀将组织切成小块。 操作中应保持组织湿润。 2) 以 lOOOg离心切碎组织 10分钟。 3)用冷匀浆缓冲液 （0.25mol/L蔗糖； 25mmol/L Tris-HCl,pH7.5; 25瞧 ol/LiiaCl; 25mmol/L MgCl2 ) 悬浮沉淀（大约 10ral/g)。 4) 在 4°C用电动匀浆器以全速匀浆组织悬液， 直至组织被完全破碎。 5) lOOOg 离心 10分钟。 6)用重悬细胞沉淀（每 O.lg最初组织样品加 l-5nil), 再以 lOOOg离心 10分钟。 7) 用裂解缓冲液重悬沉淀（每 O.lg最初组织样品加 1ml), 然后接以下 的苯酚抽提法。
2, DNA的苯酚抽提法 步骤： 1)用 1- 10ml冷 PBS洗细胞， lOOOg离心 10分钟。 2)用冷细胞裂解液 重悬浮沉淀的细胞 （lx lO8细胞 /ml) 最少应用 lOOui裂解缓冲液。 3)加 SDS 至 终浓度为 1%, 如果在重悬细胞之前将 SDS直接加入到细胞沉淀中， 细胞可能会形 成大的团块而难以破碎， 并降低的总产率。 这一点在抽提 >107细胞时特别严重。 4) 加蛋白酶 K至终浓度 200ug/ml。 5) 50°C保温反应 1小时或在 37°C轻轻振摇过夜。 6)用等体积苯酚： 氯仿： 异戊醇 （ 25: 24: 1 )抽提， 在小离心机管中离心 10分 钟。 两相应清楚分离， 否则重新进行离心。 7) 将水相转移至新管。 8)用等体积 氯仿： 异戊醇 （24: 1)抽提， 离心 10分钟。 9)将含 DNA的水相转移至新管。 然 后进行 DNA的纯化和乙醇沉淀。
3, DNA的纯化和乙醇沉淀
步骤： 1 )将 1/10体积 2mol/L醋酸钠和 2倍体积冷 100%乙醇加到 DM溶液中， 混匀。 在 -20°C放置 1小时或至过夜。 2) 离心 10分钟。 3)小心吸出或倒出乙醇。 4)用 70%冷乙醇 500ul洗涤沉淀， 离心 5分钟。 5)小心吸出或倒出乙醇。 用 500ul 冷乙醇洗涤沉淀， 离心 5分钟。 6)小心吸出或倒出乙醇， 然后在吸水纸上倒置使 残余乙醇流尽。 空气干燥 10-15 分钟， 以使表面乙醇挥发。 注意不要使沉淀完全 干燥， 否则较难重新溶解。 7) 以小体积 TE或水重悬 DNA沉淀。 低速涡旋振荡或 用滴管吹吸， 同时逐渐增加 TE, 混合至 DNA充分溶解， 每 1-5 x lO6细胞所提取的 大约加 lul。
以下第 8-13步骤仅用于必须除去污染时， 否则可直接进行第 14步骤。
8 )将 RNA酶 A加到 DNA溶液中， 终浓度为 100ug/ml, 37°C保温 30分钟。 9 )加 入 SDS和蛋白酶 K, 终浓度分别为 0.5%和 100ug/ml。 37°C保温 30分钟。 10)用 等体积的苯酚： 氯仿： 异戊醇 （ 25: 24： 1)抽提反应液， 离心 10 分钟。 11) 小 心移出水相， 用等体积的氯仿： 异戊醇 （24: 1) 重新抽提， 离心 10 分钟。 12) 小心移出水相， 加 1/10体积 2mol/L醋酸钠和 2.5体积冷乙醇， 混匀置 - 20°C 1小 时。 13)用 70°/。乙醇及 100%乙醇洗涤沉淀， 空气干燥， 重悬核酸， 过程同第 3 - 6 步骤。 14) 测定 A26。和 A28。以检测 DNA的纯度及产率。 15)分装后存放于 -20。C。 样膜的制备：
1) 取 4x2 张适当大小的硝酸纤维素膜（NC膜）， 用铅笔在其上轻轻标出点样 位置及样号， 每一探针需两张 NC膜， 以便在后面的实验步骤中分别用高强度条件 和强度条件洗膜 。
2) 吸取及对照各 15微升， 点于样膜上， 在室温中晾干。
3) 置于浸润有 0. Imol/LNaOH, 1.5mol/LNaCl的滤纸上 5分钟 （两次）， 晾干置 于浸润有 0.5mol/L Tris-HCl ( pH7.0 ), 3mol/LNaCl 的滤纸上 5分钟 （两次）， 晾 干。
4)夹于干净滤纸中， 以铝箔包好， 60- 80°C真空干燥 2小时。
探针的标记
1 ) 3μ IProbe ( 0. lOD/10 μ 1 ), 加入 2 μ IKinase缓冲液， 8—10 uCi γ— 32P— dATP+2U Kinase, 以补加至终体积 20 μ 1。
2) 37°C 保温 2小时。
3)加 1/5体积的溴酚蓝指示剂 （BPB)。
4 )过 Sephadex G-50柱。
5) 至有 32P- Probe洗出前开始收集第一峰（可用 Monitor监测）。
6) 5滴 /管， 收集 10-15管。
7)用液体闪烁仪监测同位素量
8 ) 合并第一峰的收集液后即为所需制备的 32P-Probe (第二峰为游离 γ- 32P - dATP )0
预杂交
将样膜置于塑料袋中，加入 3- 10mg预杂交液（10xDenhardt's;6xSSC, 0. lmg/ml CT DNA (小牛胸腺 DNA)。）， 封好袋口后， 68°C水浴摇 2小时。
杂交
将塑料袋剪去一角， 加入制备好的探针， 封好袋口后， 42°C水洛摇过夜。 洗膜：
高强度洗膜：
1)取出已杂交好的样膜。
2 ) 2xSSC, 0.1¾SDS中， 40。C洗 15分钟 ( 2次）。
3 ) 0. lxSSC, 0.1%SDS中， 40°C洗 15分钟 （ 2次）。
4 ) 0. lxSSC, 0.1°/。SDS中， 55°C洗 30分钟 （ 2次）， 室温晾干。
低强度洗膜：
1 )取出已杂交好的样膜。
2 ) 2xSSC, 0.1%SDS中， 37°C洗 15分钟 ( 2次）。
3 ) 0. lxSSC, 0. l°/oSDS中， 37°C洗 15分钟 （ 2次）。
4 ) 0. lxSSC, 0.1%SDS中， 40°C洗 15分钟 （ 2次）， 室温晾干。
X-光自显影: -70°C, X-光自显影 （压片时间根据杂交斑放射性强弱而定）。
实验结果：
采用低强度洗膜条件所进行的杂交实验， 以上两个探针杂交斑放射性强弱没 有明显区别； 而采用高强度洗膜条件所进行的杂交实验， 探针 1 的杂交斑放射性 强度明显强于另一个探针杂交斑的放射性强度。 因而可用探针 1 定性和定量地分 析本发明的多核苷酸在不同组织中的存在和差异表达。 工业实用性
本发明的多肽以及该多肽的拮抗剂、 激动剂和抑制剂可直接用于疾病治疗， 例如， 可治疗恶性胂瘤、 肾上腺缺乏症、 皮肤病、 各类炎症、 HIV感染和免疫 性疾病等。
LINEs是人类基因组中散布重复的长序列的家族成员。 人类长的散布重复 LINE-1 ( L1 ) 构成了一个高度重复的 DNA家族。 该 L1转录因子的表达是相对 人类特异的， 对于细胞增殖十分重要。 近来在小细胞肺癌中发现一个新的 LINE1 转录因子， 该因子的核苷酸序列与一致完整的 6. 5kb L1 中的开放阅读框 2
( 01^2 ) 有 98. 4%的相似性， 故而被称为 L1元件类 0RF2蛋白。 该蛋白对于细 胞增殖十分重要。 在体内其表达异常可影响机体对细胞增殖的调控， 进而导致 胚胎发育紊乱、 自身免疫病以及肿瘤疾病的发生。
本发明的多肽与人 L1元件类 0RF2蛋白是人 L1元件类 0RF2蛋白， 含 LINE - 1 ( L1 ) 家族的特征性序列， 两者具有相似的生物学功能， 本多肽在体内的异 常表达可影响机体对细胞增殖的调控， 进而导致胚胎发育紊乱、 自身免疫病以 及肿瘤疾病的发生， 这些疾病包括但不限于：
自身免疫性疾病
一. 结締组织疾病
类风湿关节炎， 系统性红斑狼疮， 皮肌炎， 硬皮病等；
二. 神经肌肉疾病
多发性硬化症， 重症肌无力， 脱髓鞘疾病等；
三. 内分泌性疾病
原发性肾上腺皮质萎缩， 慢性甲状腺炎， 青少年型糖尿病等；
四. 消化系统疾病
慢性非特异性溃疡性结肠炎， 慢性活动性肝炎， 恶性贫血， 萎缩性胃炎； 五. 泌尿系统疾病 自身免疫性肾小球肾炎， 肺肾出血性综合征等；
六. 血液系统疾病
自身免疫性溶血性贫血， 特发性血小板减少性紫癜， 特发性血小板减少 症等； 胚胎发育常见畸形： '
一. 颜面、 颈和四肢的常见畸形：
1. 唇裂 （最常见， 可伴有牙槽突裂和腭裂） ， 腭裂， 面斜裂， 颈囊， 颈 瘘等；
2. 四肢的常见畸形：
1 )肢体缺如：
横向缺如 （先天性短肢） ： 无臂， 无前臂， 无手， 无指， 无腿， 无 趾等；
纵向缺如： 上肢桡 /尺侧缺如， 下肢胫 /腓恻缺如等；
海豹样手 /足畸形等；
2) 肢体分化障碍： 某块肌肉或肌群缺如， 关节发育不良， 骨畸形， 骨融合， 多指 （趾）， 并指 （趾） 畸形， 马碲内翻足等；
二. 消化系统的常见畸形：
甲状舌管囊肿， 消化管闭锁或狭窄， 回肠憩室， 脐瘘， 先天性脐疝， 先天性 无神经节性巨结肠， 不通肛， 肠绊转位异常， 胆管闭锁， 环状胰等；
三. 呼吸系统的常见畸形： 喉气管狭窄 /闭锁， 气管食管瘘， 透明膜病， 单侧肺 不发生， 异位肺叶， 先天性肺囊肿， 肺膨胀不全等；
四. 泌尿系统的常见畸形： 多囊肾， 异位肾， 马碲肾， 双输尿管， 脐尿瘘， 膀 胱外翻等；
五. 生殖系统的常见畸形： 隐睾， 先天性腹股沟疝， 双子宫， 阴道闭锁， 尿道 下裂， 真 /假两性畸形， 睾丸女性化综合征等；
六. 心血管系统的常见畸形： 房间隔缺损， 室间隔缺损， 动脉干分隔异常 （主 动脉和肺动脉错位、 主动脉或肺动脉狭窄）， 动脉导管未闭等；
七. 神经系统的常见畸形： 神经管缺陷 （无脑畸形、 脊髓裂、 脊髓脊膜膨出、 积水性脑膜脑膨出） ， 脑内 /外脑积水等；
各组织肿瘤
一. 上皮组织： 乳头状瘤， 鳞 细胞癌 【皮肤、 鼻咽、 喉、 宫颈】 ， 腺瘤（癌） 【乳腺、 甲状腺】 ， 粘 /浆液性囊腺瘤（癌） 【卵巢】 ， 基底细胞癌【头面部皮肤】 ， （恶 性）多型性腺瘤 【延腺】 ， 乳头状瘤、 移行上皮癌 【膀胱、 肾盂】 等； 二. 间叶组织：
纤维（肉）瘤 【四肢】 ， （恶性）纤维组织细胞瘤 【四肢】 ， 脂肪（肉）瘤 【皮 下组织、 下肢、 腹膜后】， 平滑肌（肉）瘤【子宫和胃肠】， 横紋肌（肉）瘤【头 颈、 生殖泌尿道、 四肢】 ， 血管（肉）瘤、 淋巴管（肉）瘤 【皮肤、 皮下组织、 舌、 唇】 ， 骨（肉）瘤 【颅骨、 长骨】 ， （恶）性巨细胞瘤 【股 /胫 /肱骨上端】 , 软骨（肉）瘤 【手足短骨、 盆 /肋 /股 /肱 /肩胛骨】 ， 滑膜（肉）瘤 【膝 /踝 /腕 / 肩 /肘关节附近】 ， （恶）性间皮瘤 【胸 /腹膜】 等；
三. 淋巴造血组织：
恶性淋巴瘤 【颈部、 纵隔、 肠系膜和腹膜后淋巴结】 ， 各种白血病 【淋 巴造血组织】 ， 多发性骨髓瘤 【推 /胸 /肋 /颅骨和长骨】 等；
四. 神经组织：
神经纤维（肉）瘤【全身皮神经 /深部神经及内脏】， （恶性）神经鞘瘤【头、 颈、 四肢等处神经】 ， （恶性）胶质细胞瘤 【大脑】 ， 髓母细胞瘤 【小脑】 ， (恶性）脑膜瘤 【脑膜】 ， 节神经细胞瘤 /神经母细胞瘤 【纵隔和腹膜后 /肾 上腺髓质】 等；
五. 其他肿瘤：
黑痣， 恶性黑色素瘤 【皮肤、 粘膜】 ， （恶性）葡萄胎， 绒毛膜上皮癌 【子 宫】 ， （恶性）支持细胞、 间质细胞瘤， （恶性）颗粒细胞瘤 【卵巢、 睾丸】 , 精原细胞瘤 【睾丸】 ， 无性细胞瘤 【卵巢】 ， 胚胎性癌 【睾丸、 卵巢】 ， （恶 性）畸胎瘤 【卵巢、 睾丸、 纵隔和骶尾部】 等；
综合上述， 本发明的多肽以及该多肽的拮抗剂， 激动剂和抑制剂可直接用 于多种疾病的治疗， 例如胚胎发育紊乱、 自身免疫病以及肿瘤疾病等。
本发明也提供了筛选化合物以鉴定提高（激动剂）或阻遏（拮抗剂）人 L1元件 类 0RF2蛋白 21的药剂的方法。 激动剂提高人 L1元件类 0RF2蛋白 21刺激细胞 增殖等生物功能， 而拮抗剂阻止和治疗与细胞过度增殖有关的紊乱如各种癌症。 例如， 能在药物的存在下， 将哺乳动物细胞或表达人 L1元件类 0RF2蛋白 21的 膜制剂与标记的人 L1元件类 0RF2蛋白 21—起培养。 然后测定药物提高或阻遏 此相互作用的能力。
人 L1元件类 0RF2蛋白 21的拮抗剂包括筛选出的抗体、 化合物、 受体缺失 物和类似物等。 人 L1元件类 0RF2蛋白 21的拮抗剂可以与人 L1元件类 0RF2蛋 白 21结合并消除其功能， 或是抑制该多肽的产生， 或是与该多肽的活性位点结 合使该多肽不能发挥生物学功能。
在筛选作为拮抗剂的化合物时， 可以将人 L1元件类 0RF2蛋白 21加入生物 分析测定中， 通过测定化合物对人 L1元件类 0RF2蛋白 21和其受体之间相互作 用的影响来确定化合物是否是拮抗剂。 用上述筛选化合物的同样方法， 可以筛 选出起拮抗剂作用的受体缺失物和类似物。 能与人 L1元件类 0RF2蛋白 21结合 的多肽分子可通过筛选由各种可能组合的氨基酸结合于固相物组成的随机多肽 库而获得。 筛选时， 一般应对人 L1元件类 0RF2蛋白 21分子进行标记。
本发明提供了用多肽， 及其片段、 衍生物、 类似物或它们的细胞作为抗原 以生产抗体的方法。 这些抗体可以是多克隆抗体或单克隆抗体。 本发明还提供 了针对人 L1元件类 0RF2蛋白 21抗原决定簇的抗体。这些抗体包括（但不限于）： 多克隆抗体、 单克隆抗体、 嵌合抗体、 单链抗体、 Fab片段和 Fab表达文库产 生的片段。
多克隆抗体的生产可用人 L1元件类 0RF2蛋白 21直接注射免疫动物 （如家 兔， 小鼠， 大鼠等） 的方法得到， 多种佐剂可用于增强免疫反应， 包括但不限 于弗氏佐剂等。 制备人 L1元件类 0RF2蛋白 21的单克隆抗体的技术包括但不限 于杂交瘤技术（Kohl er and Mi l s te in. Na ture, 1975, 256: 495-497) , 三瘤技术， 人 Β-细胞杂交瘤技术， EBV-杂交瘤技术等。 将人恒定区和非人源的可变区结合 的嵌合抗体可用已有的技术生产（Morr i son et a l , PNAS, 1985， 81: 6851)。 而已 有的生产单链抗体的技术（U. S. Pa t No. 4946778)也可用于生产抗人 L1元件 0RF2蛋白 21的单链抗体。
抗人 L1元件类 0RF2蛋白 21的抗体可用于免疫组织化学技术中， 检测活检 标本中的人 L1元件类 0RF2蛋白 21。
与人 L1元件类 0RF2蛋白 21结合的单克隆抗体也可用放射性同位素标记， 注入体内可跟踪其位置和分布。 这种放射性标记的抗体可作为一种非创伤性诊 断方法用于肿瘤细胞的定位和判断是否有转移。
抗体还可用于设计针对体内某一特殊部位的免疫毒素。 如人 L1元件类 0RF2 蛋白 21高亲和性的单克隆抗体可与细菌或植物毒素（如白喉毒素， 蓖麻蛋白， 红豆碱等）共价结合。 一种通常的方法是用巯基交联剂如 SPDP , 攻击抗体的氨 基， 通过二硫键的交换， 将毒素结合于抗体上， 这种杂交抗体可用于杀灭人 L1 元件类 0RF2蛋白 21阳性的细胞。 本发明中的抗体可用于治疗或预防与人 LI元件类 0RF2蛋白 21相关 疾 病。 给予适当剂量的抗体可以刺激或阻断人 L1元件类 0RF2蛋白 21的产生或活 性。
本发明还涉及定量和定位检测人 L1元件类 0RF2蛋白 21水平的诊断试验方 法。 这些试验是本领域所熟知的， 且包括 FI SH测定和放射免疫测定。 试验中所 检测的人 L1元件类 0RF2蛋白 21水平， 可以用作解释人 L1元件类 0RF2蛋白 21 在各种疾病中的重要性和用于诊断人 L1元件类 0RF2蛋白 21起作用的疾病。
本发明的多肽还可用作肽谱分析， 例如， 多肽可用物理的、 化学或酶进行 特异性切割， 并进行一维或二维或三维的凝胶电泳分析，更好的是进行质谱分 析。
编码人 L1元件类 0RF2蛋白 21的多核苷酸也可用于多种治疗目的。 基因治 疗技术可用于治疗由于人 L1元件类 0RF2蛋白 21的无表达或异常 /无活性表达 所致的细胞增殖、 发育或代谢异常。 重组的基因治疗载体（如病毒载体）可设计 用于表达变异的人 L1元件类 0RF2蛋白 21 , 以抑制内源性的人 L1元件类 0RF2 蛋白 21活性。 例如， 一种变异的人 L1元件类 0RF2蛋白 21可以是缩短的、 缺 失了信号传导功能域的人 L1元件类 0RF2蛋白 21 , 虽可与下游的底物结合， 但 缺乏信号传导活性。 因此重组的基因治疗载体可用于治疗人 L1元件类 0RF2蛋 白 21表达或活性异常所致的疾病。 来源于病毒的表达载体如逆转录病毒、 腺病 毒、腺病毒相关病毒、单纯疱疹病毒、细小病毒等可用于将编码人 L1元件类 0RF2 蛋白 21的多核苷酸转移至细胞内。 构建携带编码人 L1元件类 0RF2蛋白 21的 多核苷酸的重组病毒载体的方法可见于已有文献（Sambrook, e t a l. )。 另外重组 编码人 L1元件类 0RF2蛋白 21的多核苷酸可包装到脂质体中转移至细胞内。
多核苷酸导入组织或细胞内的方法包括： 将多核苷酸直接注入到体内组织 中； 或在体外通过载体（如病毒、 噬菌体或质粒等）先将多核苷酸导入细胞中， 再将细胞移植到体内等。
抑制人 L1元件类 0RF2蛋白 21 mRNA的寡核苷酸（包括反义 RNA和 DNA)以 及核酶也在本发明的范围之内。 核酶是一种能特异性分解特定 RM的酶样 RNA 分子， 其作用机制是核酶分子与互补的靶 RNA特异性杂交后进行核酸内切作用。 反义的 RNA和 DNA及核酶可用已有的任何 RNA或 DNA合成技术获得， 如固相磷 酸酰胺化学合成法合成寡核苷酸的技术巳广泛应用。 反义 RNA分子可通过编码 该 RNA的 DNA序列在体外或体内转录获得。 这种 DM序列已整合到载体的 RNA 聚合酶启动子的下游。 为了增加核酸分子的稳定性， 可用多种方法对其进行修 饰， 如增加两侧的序列长度， 核糖核苷之间的连接应用磷酸硫酯键或肽键而非 磷酸二酯键。
编码人 L1元件类 0RF2蛋白 21的多核苷酸可用于与人 L1元件类 0RF2蛋白 21的相关疾病的诊断。 编码人 L1元件类 0RF2蛋白 21的多核苷酸可用于检测 人 L1元件类 0RF2蛋白 21的表达与否或在疾病状态下人 L1元件类 0RF2蛋白 21 的异常表达。 如编码人 L1元件类 0RF2蛋白 21的 DNA序列可用于对活检标本进 行杂交以判断人 L1元件类 0RF2蛋白 21的表达状况。 杂交技术包括 Sou thern 印迹法， Nor thern印迹法、 原位杂交等。 这些技术方法都是公开的成熟技术， 相关的试剂盒都可从商业途径得到。 本发明的多核苷酸的一部分或全部可作为 探针固定在微阵列（Mi croar ray)或 DNA芯片（又称为 "基因芯片" ）上， 用于分 析组织中基因的差异表达分析和基因诊断。 用人 L1元件类 0RF2蛋白 21特异的 引物进行 RNA -聚合酶链反应（RT - PCR)体外扩增也可检测人 L1元件类 0RF2蛋白 21的转录产物。
检测人 L1元件类 0RF2蛋白 21基因的突变也可用于诊断人 L1元件类 0RF2 蛋白 21相关的疾病。 人 L1元件类 0RF2蛋白 21突变的形式包括与正常野生型 人 L1元件类 0RF2蛋白 21 DNA序列相比的点突变、 易位、 缺失、 重组和其它任 何异常等。 可用已有的技术如 Sout hern印迹法、 DNA序列分析、 PCR和原位杂 交检测突变。另外，突变有可能影响蛋白的表达，因此用 Nor thern印迹法、 Wes tern 印迹法可间接判断基因有无突变。
本发明的序列对染色体鉴定也是有价值的。 该序列会特异性地针对某条人 染色体具体位置且并可以与其杂交。 目前， '需要鉴定染色体上的各基因的具体 位点。 现在， 只有很少的基于实际序列数据（重复多态性）的染色体标记物可用 于标记染色体位置。 根据本发明， 为了将这些序列与疾病相关基因相关联， 其 重要的第一步就是将这些 DM序列定位于染色体上。
简而言之， 根据 cDNA制备 PCR引物（优选 1 5- 35bp) , 可以将序列定位于染色 体上。 然后， 将这些引物用于 PCR筛选含各条人染色体的体细胞杂合细胞。 只 有那些合有相应于引物的人基因的杂合细胞会产生扩增的片段。
体细胞杂合细胞的 PCR定位法， 是将 DNA定位到具体染色体的快捷方法。 使 用本发明的寡核苷酸引物， 通过类似方法， 可利用一组来自特定染色体的片段 或大量基因组克隆而实现亚定位。 可用于染色体定位的其它类似策略包括原位 杂交、 用标记的流式分选的染色体预筛选和杂交预选， 从而构建染色体特异的 cDNA库。 将 cDNA克隆与中期染色体进行荧光原位杂交（FISH) , 可以在一个步骤中精 确地进行染色体定位。 此技术的综述， 参见 Verma等， Human Chromosomes: a Manua l of Bas ic Techniques, Pergamon Pres s, New York (1988)。
一旦序列被定位到准确的染色体位置， 此序列在染色体上的物理位置就可 以与基因图数据相关联。 这些数据可见于例如， V. Mckus ick, Mende l ian
Inher i tance in Man (可通过与 Johns Hopkins Univers i ty Wel ch Medica l Library联机获得）。 然后可通过连锁分析， 确定基因与业已定位到染色体区域 上的疾病之间的关系。
接着， 需要测定患病和未患病个体间的 cDNA或基因组序列差异。 如果在 些或所有的患病个体中观察到某突变， 而该突变在任何正常个体中未观察到， 则该突变可能是疾病的病因。 比较患病和未患病个体， 通常涉及首先寻找染色 体中结构的变化， 如从染色体水平可见的或用基于 cDNA序列的 PCR可检测的缺 失或易位。 根据目前的物理作图和基因定位技术的分辨能力， 被精确定位至与 疾病有关的染色体区域的 cDNA, 可以是 50至 500个潜在致病基因间之一种（假定 1兆碱基作图分辨能力和每 20kb对应于一个基因）。
可以将本发明的多肽、 多核苷酸及其模拟'物、 激动剂、 拮抗剂和抑制剂与 合适的药物载体组合后使用。 这些载体可以是水、 葡萄糖、 乙醇、 盐类、 缓冲 液、 甘油以及它们的组合。 组合物包含安全有效量的多肽或拮抗剂以及不影响 药物效果的载体和赋形剂。 这些组合物可以作为药物用于疾病治疗。
本发明还提供含有一种或多种容器的药盒或试剂盒， 容器中装有一种或多 种本发明的药用组合物成分。 与这些容器一起， 可以有由制造、 使用或销售药 品或生物制品的政府管理机构所给出的指示性提示， 该提示反映出生产、 使用 或销售的政府管理机构许可其在人体上施用。 此外， 本发明的多肽可以与其它 的治疗化合物结合使用。
药物组合物可以以方便的方式给药， 如通过局部、 静脉内、 腹膜内、 肌内、 皮下、 鼻内或皮内的给药途径。 人 L1元件类 0RF2蛋白 21以有效地治疗和 /或预防 具体的适应症的量来给药。 施用于患者的人 L1元件类 0RF2蛋白 21的量和剂量范 围将取决于许多因素， 如给药方式、 待治疗者的健康条件和诊断医生的判断。

Claims

权 利 说 明 书
1、 一种分离的多肽-人 L1元件类 0RF2蛋白 21， 其特征在于它包含有： SEQ ID NO: 2所示的氨基酸序列的多肽、 或其多肽的活性片段、 类似物或衍生物。
2、 如权利要求 1所述的多肽， 其特征在于所述多肽、 类似物或衍生物的氨基 酸序列具有与 SEQ ID NO: 2所示的氨基酸序列至少 95%的相同性。
3、 如权利要求 2所述的多肽， 其特征在于它包含具有 SEQ ID NO: 2所示的氨 基酸序列的多肽。
4、 一种分离的多核苷酸， 其特征在于所述多核苷酸包含选自下组中的一种： (a) 编码具有 SEQ ID NO: 2所示氨基酸序列的多肽或其片段、 类似物、 衍生 物的多核苷酸；
(b) 与多核苷酸 （a ) 互补的多核苷酸； 或
(c) 与 （a ) 或 （b ) 有至少 70½相同性的多核苷酸。
5、 如权利要求 4所述的多核苷酸， 其特征在于所述多核苷酸包含编码具有 SEQ ID NO: 2所示氨基酸序列的多核苷酸。
6、如权利要求 4所述的多核苷酸，其特征在于所述多核苷酸的序列包含有 SEQ ID NO: 1中 860-1426位的序列或 SEQ ID NO: 1中 1-1467位的序列。
7、 一种含有外源多核苷酸的重组载体， 其特征在于它是由权利要求 4- 6中的 任一权利要求所述多核苷酸与质粒、 病毒或运载体表达载体构建而成的重组载 体。
8、 一种含有外源多核苷酸的遗传工程化宿主细胞， 其特征在于它是选自于下 列一种宿主细胞：
(a) 用权利要求 7所述的重组载体转化或转导的宿主细胞； 或
(b) 用权利要求 4-6中的任一权利要求所述多核苷酸转化或转导的宿主细 胞。
9、 一种具有人 L1元件类 0RF2蛋白 21活性的多肽的制备方法， 其特征在于所 述方法包括：
(a) 在表达人 L1元件类 0RF2蛋白 21条件下， 培养权利要求 8所述的工程 化宿主细胞；
(b) 从培养物中分离出具有人 L1元件类 0RF2蛋白 21活性的多肽。
10、 一种能与多肽结合的抗体,其特征在于所述抗体是能与人 L1元件类 0RF2 蛋白 21特异性结合的抗体。
11、 一类模拟或调节多肽活性或表达的化合物， 其特征在于它们是模拟、 促进、 拮抗或抑制人 L1元件类 0RF2蛋白 21的活性的化合物。
12、 如权利要求 11所述的化合物， 其特征在于它是 SEQ ID NO: 1所示的多核苷 酸序列或其片段的反义序列。
13、 一种权利要求 11所述化合物的应用， 其特征在于所述化合物用于调节人 L1 元件类 0RF2蛋白 21在体内、 体外活性的方法。
14、 一种检测与权利要求 1-3中的任一权利要求所述多肽相关的疾病或疾病易 感性的方法， 其特征在于其包括检测所述多肽的表达量， 或者检测所述多肽的 活性， 或者检测多核苷酸中引起所述多肽表达量或活性异常的核苷酸变异。
15、 如杈利要求 1-3中的任一权利要求所述多肽的应用， 其特征在于它应用于 筛选人 L1元件类 0RF2蛋白 21的模拟物、 激动剂， 拮抗剂或抑制剂； 或者用 于肽指紋图谱鉴定。
16、 如权利要求 4- 6 中的任一权利要求所述的核酸分子的应用， 其特征在于它 作为引物用于核酸扩增反应， 或者作为探针用于杂交反应， 或者用于制造基因 芯片或微阵列。
17、 如权利要求 1-6及 11中的任一权利要求所述的多肽、 多核苷酸或化合物 的应用， 其特征在于用所述多肽、 多核苷酸或其模拟物、 激动剂、 拮抗剂或抑 制剂以安全有效剂量与药学上可接受的载体组成作为诊断或治疗与人 L1元件 类 0RF2蛋白 21异常相关的疾病的药物组合物。
18、 权利要求 1-6及 11中的任一杈利要求所述的多肽、 多核苷酸或化合物的 应用， 其特征在于用所述多肽、 多核苷酸或化合物制备用于治疗如恶性肿瘤， 血液病， HIV感染和免疫性疾病和各类炎症的药物。
PCT/CN2001/001002 2000-06-19 2001-06-18 Nouveau polypeptide, proteine orf2 humaine 21 a element de type l1, et polynucleotide codant ce polypeptide Ceased WO2002011510A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU93633/01A AU9363301A (en) 2000-06-19 2001-06-18 A novel polypeptide-human l1 motif-like orf2 protein 21 and the polynucleotide encoding said polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN00116564.X 2000-06-19
CN00116564A CN1329034A (zh) 2000-06-19 2000-06-19 一种新的多肽——人l1元件类orf2蛋白21和编码这种多肽的多核苷酸

Publications (1)

Publication Number Publication Date
WO2002011510A1 true WO2002011510A1 (fr) 2002-02-14

Family

ID=4585968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/001002 Ceased WO2002011510A1 (fr) 2000-06-19 2001-06-18 Nouveau polypeptide, proteine orf2 humaine 21 a element de type l1, et polynucleotide codant ce polypeptide

Country Status (3)

Country Link
CN (1) CN1329034A (zh)
AU (1) AU9363301A (zh)
WO (1) WO2002011510A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002560A2 (en) * 1996-07-12 1998-01-22 Institute Of Molecular Biotechnology Genomic sequence of rhizobium sp. ngr 234 symbiotic plasmid
WO1999015644A2 (en) * 1997-09-19 1999-04-01 Universite Laval Method for the identification of essential genes and therapeutic targets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002560A2 (en) * 1996-07-12 1998-01-22 Institute Of Molecular Biotechnology Genomic sequence of rhizobium sp. ngr 234 symbiotic plasmid
WO1999015644A2 (en) * 1997-09-19 1999-04-01 Universite Laval Method for the identification of essential genes and therapeutic targets

Also Published As

Publication number Publication date
AU9363301A (en) 2002-02-18
CN1329034A (zh) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2001072812A1 (fr) Nouveau polypeptide, bromodomaine humain 10, et polynucleotide codant pour ce polypeptide
WO2002000707A1 (fr) Nouveau polypeptide, proteine humaine 10 contenant un domaine p, et polynucleotide codant ce polypeptide
WO2001083780A1 (en) A novel polypeptide, a human methylthioadenosine phosphorylase 37 and the polynucleotide encoding the polypeptide
WO2002000829A2 (fr) Nouveau polypeptide, proteine humaine 16.83 ftsh, et polynucleotide codant ce polypeptide
WO2002011510A1 (fr) Nouveau polypeptide, proteine orf2 humaine 21 a element de type l1, et polynucleotide codant ce polypeptide
WO2002048355A1 (fr) Nouveau polypeptide, proteine garp humaine 12.98, et polynucleotide codant ce polypeptide
WO2002033077A1 (fr) Nouveau polypeptide, une proteine de regulation 10.01 etant associee au developpement humain et polynucleotide la codant
WO2002006335A1 (en) A novel polypeptide - human serine/threonine protein kinase 16.17 and a polynucleotide encoding the same
WO2001072796A1 (fr) Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 11, et polynucleotide codant pour ce polypeptide
WO2002020605A1 (fr) Nouveau polypeptide, appele proteine de fixation de cycline e de cellule humaine 1(ceb1)113-70.07, et polynucleotide codant ce polypeptide
WO2001094530A2 (en) A novel polypeptide, a scan zinc-finger protein subfamily protein 57 and the polynucleotide encoding the polypeptide
WO2002026793A1 (fr) Nouveau polypeptide, grande proteine humaine 62, et polynucleotide codant ce polypeptide
WO2001040297A1 (fr) Nouveau polypeptide, proteine nucleaire de transition humaine 10 contenant un domaine de liaison atp/gtp, et polynucleotide codant pour ce polypeptide
WO2001079279A1 (fr) Nouveau polypeptide, facteur humain associe au recepteur du facteur de necrose tumorale 16, et polynucleotide codant pour ce polypeptide
WO2001081391A1 (fr) Nouveau polypeptide, proteine 29 semblable a g-beta, et polynucleotide codant pour ce polypeptide
WO2001046437A1 (fr) Nouveau polypeptide, region de liaison d'arn-eucaryote rnp-1-21, et polynucleotide codant pour ce polypeptide
WO2001047975A1 (fr) Nouveau polypeptide, proteine 10 contenant un domaine chromo, et polynucleotide codant pour ce polypeptide
WO2001070803A1 (fr) Nouveau polypeptide, proteine humaine de regulation de la transcription 9.7, et polynucleotide codant pour ce polypeptide
WO2002004506A1 (fr) Nouveau polypeptide, proteine humaine de liaison de l'arn 19, et polynucleotide codant ce polypeptide
WO2001074866A1 (fr) Nouveau polypeptide, protéine humaine a doigt de zinc 72, et polynucléotide codant pour ce polypeptide
WO2001075120A1 (fr) Nouveau polypeptide, alkylguanine-adn/cysteine proteine methyltransferase humaine 13, et polynucleotide codant pour ce polypeptide
WO2001047997A1 (fr) Nouveau polypeptide, stathmine 8, et polynucleotide codant pour ce polypeptide
WO2002020582A1 (fr) Nouveau polypeptide constitue de la proteine 9.24 amplifiee par neurofibrome homo et polynucleotide codant ledit polypeptide
WO2001074874A1 (fr) Nouveau polypeptide, facteur humain de regulation de la transcription 54, et polynucleotide codant pour ce polypeptide
WO2002004631A1 (fr) Nouveau polypeptide, proteine 11 humaine associee a la transcription inverse orf2 du facteur l1, et polynucleotide codant ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP